
USF Patents

October 2020

Methods and compositions for treating drug resistance in cancer

Subhra Mohapatra

Shyam S. Mohapatra

Mark Howell

Rajesh Nair

Follow this and additional works at: https://digitalcommons.usf.edu/usf_patents

Recommended Citation

Mohapatra, Subhra; Mohapatra, Shyam S.; Howell, Mark; and Nair, Rajesh, "Methods and compositions for treating drug resistance in cancer" (2020). *USF Patents*. 1205.
https://digitalcommons.usf.edu/usf_patents/1205

This Article is brought to you for free and open access by Digital Commons @ University of South Florida. It has been accepted for inclusion in USF Patents by an authorized administrator of Digital Commons @ University of South Florida. For more information, please contact digitalcommons@usf.edu.



US010813935B2

(12) **United States Patent**
Mohapatra et al.

(10) **Patent No.:** **US 10,813,935 B2**
(45) **Date of Patent:** **Oct. 27, 2020**

(54) **METHODS AND COMPOSITIONS FOR
TREATING DRUG RESISTANCE IN CANCER**

(71) Applicants: **UNIVERSITY OF SOUTH
FLORIDA**, Tampa, FL (US);
**TRANSGENEX NANOBIOTECH,
INC.**, Lutz, FL (US)

(72) Inventors: **Subhra Mohapatra**, Lutz, FL (US);
Shyam S. Mohapatra, Lutz, FL (US);
Mark Howell, Tampa, FL (US); **Rajesh
Nair**, Tampa, FL (US)

(73) Assignees: **TRANSGENEX NANOBIOTECH,
INC.**, Lutz, FL (US); **University of
South Florida**, Tampa, FL (US)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.

(21) Appl. No.: **15/904,176**

(22) Filed: **Feb. 23, 2018**

(65) **Prior Publication Data**

US 2018/0256579 A1 Sep. 13, 2018

Related U.S. Application Data

(60) Provisional application No. 62/462,812, filed on Feb.
23, 2017.

(51) **Int. Cl.**

A61K 31/517 (2006.01)
A61P 35/00 (2006.01)
A61K 31/496 (2006.01)

(52) **U.S. Cl.**

CPC **A61K 31/517** (2013.01); **A61P 35/00**
(2018.01); **A61K 31/496** (2013.01); **A61K**
2300/00 (2013.01)

(58) **Field of Classification Search**

CPC **A61K 2300/00**; **A61K 31/496**; **A61P 35/00**
USPC 435/6.1, 91.1, 91.31, 455, 458; 514/1, 2,
514/44 A; 536/23.1, 24.5
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,554,101 A 11/1985 Hopp
4,870,287 A 9/1989 Cole et al.
5,580,859 A 12/1996 Felgner et al.
5,676,646 A 10/1997 Hofmann et al.
5,679,647 A 10/1997 Carson et al.
5,702,359 A 12/1997 Hofmann et al.

5,703,055 A 12/1997 Felgner et al.
5,760,395 A 6/1998 Johnstone
6,068,650 A 5/2000 Hofmann et al.
6,096,020 A 8/2000 Hofmann
6,120,493 A 9/2000 Hofmann
6,150,148 A 11/2000 Nanda et al.
6,181,964 B1 1/2001 Hofmann et al.
6,192,270 B1 2/2001 Hofmann et al.
6,208,893 B1 3/2001 Hofmann
6,216,034 B1 4/2001 Hofmann et al.
6,233,482 B1 5/2001 Hofmann et al.
6,241,701 B1 6/2001 Hofmann
6,302,874 B1 10/2001 Zhang et al.
7,664,545 B2 2/2010 Westersten et al.
2015/0152474 A1* 6/2015 Pawlowski C12Q 1/6886
506/4
2019/0000763 A1* 1/2019 Pilgaonkar A61K 9/5031

OTHER PUBLICATIONS

Fan et al, Cancer Res., vol. 71, No. 13, pp. 4494-4505 (Year:
2011).
Wang et al, J. Hematology and Oncology, vol. 9, No. 34, pp. 1-7
(Year: 2016).
Janne et al, NEJM, vol. 372, No. 18, pp. 1689-1699 (Year: 2015).
American Cancer Society, Cancer Facts and Figures 2017.
C.T.F.A. Cosmetic Ingredient Handbook, 1992, pp. 587-592.
Costa et al., "Whacking a mole-cule: clinical activity and mecha-
nisms of resistance to third generation EGFR inhibitors in EGFR
mutated lung cancer with EGFR-1790M," Transl Lung Cancer Res,
2015, 4(6): 809-815.
Donnelly et al., "DNA vaccines," Ann. Rev. Immunol., 1997,
15:617-648.
Fan et al., "MET-independent lung cancer cells evading EGFR
kinase inhibitors are therapeutically susceptible to BH3 mimetic
agents," Cancer Res, 2011, 71(3): 4494-4505.
Girard et al., "A 3D fibrous scaffold inducing tumoroids: a platform
for anti-cancer drug development," PloS one, 2013. 8(10): e75345.
Heagerty et al., "Time-dependent ROC curves for censored survival
data and a diagnostic marker," Biometrics, 2000, 56(2):337-44.
Howell et al., "Mechanism of Treatment-induced Drug Resistance
in Lung Cancer," 2017.
Janne et al., "AZD9291 in EGFR inhibitor-resistant non-small-cell
lung cancer," N Engl J Med, 2015, 372(18): 1689-1699.

(Continued)

Primary Examiner — Jane J Zara

(74) *Attorney, Agent, or Firm* — Fish & Richardson P.C.

(57)

ABSTRACT

Disclosed herein are compositions and methods for treating
cancer. Further provided herein are compositions and meth-
ods for reducing, inhibiting, or preventing resistance of
cancer to tyrosine kinase inhibitors. The methods may
include administering an anti-resistance agent such as a
CYP51A1 inhibitor or an agonist of miRNA-764 (SEQ ID
NO: 4) to a subject. A tyrosine kinase inhibitor may also be
administered to the subject in addition to the anti-resistance
agent.

12 Claims, 5 Drawing Sheets

Specification includes a Sequence Listing.

(56)

References Cited

OTHER PUBLICATIONS

Kyle et al., "A simple method for displaying the hydropathic character of a protein," J. Mol. Biol., 1982, 157(1):105-132.

McCutcheon's vol. 1, Emulsifiers & Detergents, 1994, North American Edition, pp. 236-239.

Remington's Pharmaceutical Sciences, 15th Ed. 1975, pp. 335-337.

Song et al., "Dual inhibition of MEK1/2 and EGFR synergistically induces caspase-3-dependent apoptosis in EGFR inhibitor-resistant lung cancer cells via BIM upregulation," Invest New Drugs, 2013, 31(6): 1458-1465.

Wang et al., "Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors," Front Med, 2016, 10(4): 383-388.

Wang, et al., "Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer," J Hematol Oncol, 2016, 9: p. 34.

Wheeler et al., "Understanding resistance to EGFR inhibitors-impact on future treatment strategies," Nat Rev Clin Oncol, 2010, 7(9): 493-507.

Yver, "Osimertinib (AZD9291)-science-driven, collaborative approach to rapid drug design and development," Ann Oncol, 2016, 27(6): 1165-1170.

* cited by examiner




FIG. 1




FIG. 2A





FIG. 2B




FIG. 3A





FIG. 3B



1

METHODS AND COMPOSITIONS FOR TREATING DRUG RESISTANCE IN CANCER

CROSS-REFERENCE TO RELATED APPLICATION(S)

This application claims priority to U.S. Provisional Patent Application No. 62/462,812, filed Feb. 23, 2017, which is incorporated herein by reference in its entirety.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH

This invention was made with government support under grants R01CA152005, HHSN261201400022C, and HHSN261201300044C awarded by the National Cancer Institute (NCI) of the National Institutes of Health (NIH). The government has certain rights in the invention.

INCORPORATION-BY-REFERENCE OF MATERIAL SUBMITTED ELECTRONICALLY

Incorporated by reference in its entirety herein is a computer-readable nucleotide/amino acid sequence listing submitted concurrently herewith and identified as follows: One 36,492 Bytes ASCII (Text) file named "17A023PRC-210112-9029-US02_ST25.txt", created on May 21, 2018.

FIELD

This disclosure relates to cancer therapies, as well as preventing or reducing drug resistance in cancer.

INTRODUCTION

Lung cancer is the number one cause of cancer related death in both males and females. About 20% of all non-small cell lung cancer (NSCLC) patients are expected to harbor an epidermal growth factor receptor (EGFR) activating mutation. EGFR inhibitors have been shown to provide clinical benefits over chemotherapy for lung cancer patients with EGFR activating mutations. First- and second-generation EGFR tyrosine kinase inhibitors (TKIs) are clinically approved to treat advanced NSCLC patients. However, despite the initial clinical responses to these EGFR targeted therapies, long-term efficacy is currently not possible because acquired drug resistance to the EGFR inhibitors hampers the effectiveness of these therapies. Effective treatments are yet to be discovered.

SUMMARY

In an aspect, the disclosure relates to methods of treating cancer in a subject. The methods may include administering to the subject a tyrosine kinase inhibitor and an anti-resistance agent. In some embodiments, the tyrosine kinase inhibitor and the anti-resistance agent are co-administered to the subject. In some embodiments, the tyrosine kinase inhibitor is administered to the subject prior to the anti-resistance agent. In some embodiments, the anti-resistance agent is administered to the subject prior to the tyrosine kinase inhibitor.

In a further aspect, the disclosure relates to methods of treating cancer in a subject undergoing treatment with a tyrosine kinase inhibitor. The methods may include admin-

2

istering to the subject an anti-resistance agent. In some embodiments, the cancer is a tyrosine kinase inhibitor-resistant cancer.

Another aspect of the disclosure provides methods for preventing drug resistance or enhancing the therapeutic efficacy of a tyrosine kinase inhibitor in a subject having cancer and undergoing treatment with the tyrosine kinase inhibitor. The methods may include administering to the subject a pharmaceutical composition comprising an anti-resistance agent in an amount effective to attenuate resistance to the tyrosine kinase inhibitor.

Another aspect of the disclosure provides methods of sensitizing a tyrosine kinase inhibitor-resistant cancer in a subject to the tyrosine kinase inhibitor. The methods may include administering to the subject an anti-resistance agent.

In some embodiments, the anti-resistance agent comprises a CYP51A1 inhibitor, or an agonist of SEQ ID NO: 4 (miRNA-764), or a combination thereof. In some embodiments, the anti-resistance agent comprises a CYP51A1 inhibitor. In some embodiments, the CYP51A1 inhibitor comprises ketoconazole. In some embodiments, the anti-resistance agent comprises an agonist of SEQ ID NO: 4 (miRNA-764). In some embodiments, the anti-resistance agent comprises a polynucleotide having a sequence of SEQ ID NO: 4 (miRNA-764). In some embodiments, the cancer comprises non-small cell lung cancer (NSCLC). In some embodiments, acquired drug resistance to the tyrosine kinase inhibitor is decreased or prevented. In some embodiments, tyrosine kinase inhibitor resistance is decreased at least 2-fold. In some embodiments, tyrosine kinase inhibitor resistance is decreased at least 5-fold. In some embodiments, the activity of the tyrosine kinase inhibitor is increased at least 2-fold. In some embodiments, the activity of the tyrosine kinase inhibitor is increased at least 5-fold. In some embodiments, tyrosine kinase inhibitor comprises lapatinib.

The disclosure provides for other aspects and embodiments that will be apparent in light of the following detailed description and accompanying figures.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a schematic of the proposed mechanism of action for ketoconazole.

FIG. 2A and FIG. 2B are graphs showing the establishment of multi-drug resistant cell lines. Shown in FIG. 2A is the drug sensitivity in parental- and DR-cell lines. Average luminescence as a percentage of control in lapatinib treated cultures on the monolayer (blue/dark gray) and the scaffold (red/light gray) is shown. Shown in FIG. 2B are images of the H1975 cell line grown on 3D fibrous scaffold (100×).

FIG. 3A, FIG. 3B, and FIG. 3C are images, gels, and graphs of an analysis of drug-resistant cells compared to parental cell lines. Shown in FIG. 3A are 500,000 H1650 cells that were plated in 1 well of a 6-well plate and treated with the indicated drugs at the time of plating and allowed to grow for 72 hours. Microscopy pictures were taken using bright field microscopy at 100×. Shown in FIG. 3B is a Western blot analysis of the expression of cleaved EGFR, p-EGFR, and CYP51A1 from whole cell lysates, showing that ketoconazole induced lowering of EGFR downstream signaling. Cells were treated with lapatinib or ketoconazole for 48 hours. β -Actin was included as a loading control. FIG. 3C are graphs of the densitometry of the western blot bands, as performed using ImageJ software.

DETAILED DESCRIPTION

Described herein are methods and compositions for treating cancer, and for preventing resistance to an antiprolifera-

tive drug or enhancing its therapeutic effect in a subject. Using multi-drug resistant cell lines and a 3D culture platform, we have found that treatment with an inhibitor of CYP51A1 can sensitize drug resistant cancer to continued treatment with the drug. We have also discovered that miR-764 (SEQ ID NO: 4) is downregulated in multi-drug resistant cancer cell lines. Inhibitors of CYP51A1 and/or agonists of miR-764 (SEQ ID NO: 4) may be used alone or in combination with an antiproliferative drug to prevent acquired resistance to the antiproliferative drug. Overexpression of miR-764 (SEQ ID NO: 4) or inhibition of CYP51A1 can be used as therapeutics to sensitize drug resistant cancers and/or prevent acquired drug resistance.

1. DEFINITIONS

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. In case of conflict, the present document, including definitions, will control. Preferred methods and materials are described below, although methods and materials similar or equivalent to those described herein can be used in practice or testing of the present invention. All publications, patent applications, patents and other references mentioned herein are incorporated by reference in their entirety. The materials, methods, and examples disclosed herein are illustrative only and not intended to be limiting.

The terms “comprise(s),” “include(s),” “having,” “has,” “can,” “contain(s),” and variants thereof, as used herein, are intended to be open-ended transitional phrases, terms, or words that do not preclude the possibility of additional acts or structures. The singular forms “a,” “and” and “the” include plural references unless the context clearly dictates otherwise. The present disclosure also contemplates other embodiments “comprising,” “consisting of” and “consisting essentially of,” the embodiments or elements presented herein, whether explicitly set forth or not.

For the recitation of numeric ranges herein, each intervening number there between with the same degree of precision is explicitly contemplated. For example, for the range of 6-9, the numbers 7 and 8 are contemplated in addition to 6 and 9, and for the range 6.0-7.0, the number 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, and 7.0 are explicitly contemplated.

The term “about” as used herein as applied to one or more values of interest, refers to a value that is similar to a stated reference value. In certain aspects, the term “about” refers to a range of values that fall within 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less in either direction (greater than or less than) of the stated reference value unless otherwise stated or otherwise evident from the context (except where such number would exceed 100% of a possible value).

The term “administration” or “administering,” as used herein, refers to providing, contacting, and/or delivery of an agent by any appropriate route to achieve the desired effect. These agents may be administered to a subject in numerous ways including, but not limited to, orally, ocularly, nasally, intravenously, topically, as aerosols, suppository, etc. and may be used in combination.

“Amino acid” as used herein refers to naturally occurring and non-natural synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code. Amino acids can be referred to herein by either their

commonly known three-letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Amino acids include the side chain and polypeptide backbone portions.

The term “agonist” refers to a biologically active ligand that binds to its complementary biologically active receptor and activates the receptor either to cause a biological response in the receptor or to enhance a biological activity of the receptor. An agonist may trigger (e.g., initiate or promote), partially or fully enhance, stimulate, increase, or activate one or more biological activities. An agonist may mimic the action of a naturally occurring substance. Whereas an agonist causes an action, an antagonist blocks the action of the agonist.

“Antagonist” or “inhibitor” may be used interchangeably and refers to an agent that inhibits the effect of an agonist. An antagonist may be a compound that inhibits or reduces an activity of a polypeptide. An antagonist may indirectly or directly bind a polypeptide and inhibit the activity of the polypeptide, including binding activity or catalytic activity. For example, an antagonist may prevent expression of a polypeptide, or inhibit the ability of a polypeptide to mediate the binding of the polypeptide to a ligand. An “allosteric antagonist” refers to a compound that binds to a polypeptide at a secondary site, distinct from the primary ligand binding site, and inhibits or reduces an activity of the polypeptide. The terms “inhibit” or “inhibiting” mean that an activity is decreased or prevented in the presence of an inhibitor as opposed to in the absence of the inhibitor. The term “inhibition” refers to the reduction or down regulation of a process or the elimination of a stimulus for a process, which results in the absence or minimization of the expression or activity of a biomolecule or polypeptide. Inhibition may be direct or indirect. Inhibition may be specific, that is, the inhibitor inhibits a biomolecule or polypeptide and not others.

“Cancer” refers to a neoplasm or tumor resulting from abnormal and uncontrolled growth of cells. Cancer may also be referred to as a cellular-proliferative disease. Cancer may include different histological types, cell types, and different stages of cancer, such as, for example, primary tumor or metastatic growth. Cancer may include, for example, breast cancer, cholangiocellular carcinoma, colorectal cancer, endometriosis, esophageal cancer, gastric cancer, diffused type gastric cancer, pancreatic cancer, renal carcinoma, soft tissue tumor, testicular cancer, cardiac: sarcoma (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyoma, fibroma, lipoma and teratoma; Lung: bronchogenic carcinoma (squamous cell, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hamartoma, mesothelioma, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC); Gastrointestinal: esophagus (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, vipoma), small bowel (adenocarcinoma, lymphoma, carcinoid tumors, Kaposi’s sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large bowel (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma); Genitourinary tract: kidney (adenocarcinoma, Wilms’ tumor [nephroblastoma], lymphoma, leukemia), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), testis (seminoma, teratoma, embryonal

carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, lipoma); Liver: hepatoma (hepatocellular carcinoma), cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma; Bone: osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochondroma (osteochondrogenous exostoses), benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma and giant cell tumors; Nervous system: skull (osteoma, hemangioma, granuloma, xanthoma, osteitis deformans), meninges (meningioma, meningiosarcoma, gliomatosis), brain (astrocytoma, medulloblastoma, glioma, ependymoma, germinoma [pinealoma], glioblastoma, glioblastoma multiform, oligodendroglioma, schwannoma, retinoblastoma, congenital tumors), spinal cord neurofibroma, meningioma, glioma, sarcoma); Gynecological: uterus (endometrial carcinoma), cervix (cervical carcinoma, pre-tumor cervical dysplasia), ovaries (ovarian cancer, ovarian carcinoma [serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma], granulosa-thecal cell tumors, Sertoli-Leydig cell tumors, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal rhabdomyosarcoma), fallopian tubes (carcinoma); Hematologic: blood (myeloid leukemia [acute and chronic], acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative diseases, multiple myeloma, myelodysplastic syndrome), Hodgkin's disease, non-Hodgkin's lymphoma [malignant lymphoma], CML; Skin: melanoma, malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Karposi's sarcoma, moles, dysplastic nevi, lipoma, angioma, dermatofibroma, keloids, psoriasis; and Adrenal glands: neuroblastoma. In some embodiments, the cancer comprises non-small cell lung cancer (NSCLC). In some embodiments, the cancer is resistant to a therapy. In some embodiments, the cancer is not resistant to a therapy.

The terms "control," "reference level," and "reference" are used herein interchangeably. The reference level may be a predetermined value or range, which is employed as a benchmark against which to assess the measured result. "Control group" as used herein refers to a group of control subjects. The predetermined level may be a cutoff value from a control group. The predetermined level may be an average from a control group. Cutoff values (or predetermined cutoff values) may be determined by Adaptive Index Model (AIM) methodology. Cutoff values (or predetermined cutoff values) may be determined by a receiver operating curve (ROC) analysis from biological samples of the patient group. ROC analysis, as generally known in the biological arts, is a determination of the ability of a test to discriminate one condition from another, e.g., to determine the performance of each marker in identifying a patient having CRC. A description of ROC analysis is provided in P. J. Heagerty et al. (*Biometrics* 2000, 56, 337-44), the disclosure of which is hereby incorporated by reference in its entirety. Alternatively, cutoff values may be determined by a quartile analysis of biological samples of a patient group. For example, a cutoff value may be determined by selecting a value that corresponds to any value in the 25th-75th percentile range, preferably a value that corresponds to the 25th percentile, the 50th percentile or the 75th percentile, and more preferably the 75th percentile. Such statistical analyses may be

performed using any method known in the art and can be implemented through any number of commercially available software packages (e.g., from Analyse-it Software Ltd., Leeds, UK; StataCorp LP, College Station, Tex.; SAS Institute Inc., Cary, N.C.). The healthy or normal levels or ranges for a target or for a protein activity may be defined in accordance with standard practice. A control may be a subject, or a sample therefrom, whose disease state is known. The subject, or sample therefrom, may be healthy, diseased, diseased prior to treatment, diseased during treatment, diseased after treatment, or healthy after treatment, or a combination thereof. The term "normal subject" as used herein means a healthy subject, i.e. a subject having no clinical signs or symptoms of disease. The normal subject is clinically evaluated for otherwise undetected signs or symptoms of disease, which evaluation may include routine physical examination and/or laboratory testing. In some embodiments, the control is a healthy control. In some embodiments, the control comprises cancer.

"Polynucleotide" as used herein can be single stranded or double stranded, or can contain portions of both double stranded and single stranded sequence. The polynucleotide can be nucleic acid, natural or synthetic, DNA, genomic DNA, cDNA, RNA, or a hybrid, where the polynucleotide can contain combinations of deoxyribo- and ribonucleotides, and combinations of bases including uracil, adenine, thymine, cytosine, guanine, inosine, xanthine hypoxanthine, isocytosine, and isoguanine. Polynucleotides can be obtained by chemical synthesis methods or by recombinant methods.

Polynucleotides are said to have "5' ends" and "3' ends" because mononucleotides are reacted to make oligonucleotides in a manner such that the 5' phosphate of one mononucleotide pentose ring is attached to the 3' oxygen of its neighbor in one direction via a phosphodiester linkage. Therefore, an end of an oligonucleotide is referred to as the "5' end" if its 5' phosphate is not linked to the 3' oxygen of a mononucleotide pentose ring and as the "3' end" if its 3' oxygen is not linked to a 5' phosphate of a subsequent mononucleotide pentose ring. As used herein, a polynucleotide sequence, even if internal to a larger oligonucleotide, also may be said to have 5' and 3' ends. In either a linear or circular polynucleotide, discrete elements are referred to as being "upstream" or 5' of the "downstream" or 3' elements. This terminology reflects the fact that transcription proceeds in a 5' to 3' fashion along the polynucleotide strand. The promoter and enhancer elements which direct transcription of a linked gene are generally located 5' or upstream of the coding region. However, enhancer elements can exert their effect even when located 3' of the promoter element and the coding region. Transcription termination and polyadenylation signals are located 3' or downstream of the coding region.

As used herein, the term "gene" means the polynucleotide sequence comprising the coding region of a gene, e.g., a structural gene, and the including sequences located adjacent to the coding region on both the 5' and 3' ends for a distance of about 1 kb on either end such that the gene corresponds to the length of the full-length mRNA. The sequences which are located 5' or upstream of the coding region and which are present on the mRNA are referred to as 5' non-translated sequences. The sequences which are located 3' or downstream of the coding region and which are present on the mRNA are referred to as 3' non-translated sequences. The term "gene" encompasses both cDNA and genomic forms of a gene. A genomic form or clone of a gene contains the coding region interrupted with non-coding

sequences termed “introns” or “intervening regions” or “intervening sequences.” Introns are segments of a gene which are transcribed into nuclear RNA, for example, heterogeneous nuclear RNA (hnRNA); introns may contain regulatory elements such as enhancers. Introns are removed or “spliced out” from the nuclear or primary transcript; introns therefore are absent in the messenger RNA (mRNA) transcript. The mRNA functions during translation to specify the sequence or order of amino acids in a nascent polypeptide. In addition to containing introns, genomic forms of a gene may also include sequences located on both the 5' and 3' end of the sequences which are present on the RNA transcript. These sequences are referred to as “flanking” sequences or regions (these flanking sequences are located 5' or 3' to the non-translated sequences present on the mRNA transcript). The 5' flanking region may contain regulatory sequences such as promoters and enhancers which control or influence the transcription of the gene. The 3' flanking region may contain sequences which direct the termination of transcription, post-transcriptional cleavage and polyadenylation.

As used herein, an oligonucleotide or polynucleotide “having a nucleotide sequence encoding a gene” means a polynucleotide sequence comprising the coding region of a gene, or in other words, the nucleic acid sequence which encodes a gene product. The coding region may be present in either a cDNA, genomic DNA, or RNA form. When present in a DNA form, the oligonucleotide may be single-stranded (i.e., the sense strand) or double-stranded. Suitable control elements such as enhancers/promoters, splice junctions, polyadenylation signals, etc. may be placed in close proximity to the coding region of the gene if needed to permit proper initiation of transcription and/or correct processing of the primary RNA transcript. Alternatively, the coding region utilized in the vector may contain endogenous enhancers/promoters, splice junctions, intervening sequences, polyadenylation signals, etc., or a combination of both endogenous and exogenous control elements.

A “peptide” or “polypeptide” is a linked sequence of two or more amino acids linked by peptide bonds. The polypeptide can be natural, synthetic, or a modification or combination of natural and synthetic. Peptides and polypeptides include proteins such as binding proteins, receptors, and antibodies. The terms “polypeptide”, “protein,” and “peptide” are used interchangeably herein. “Primary structure” refers to the amino acid sequence of a particular peptide. “Secondary structure” refers to locally ordered, three dimensional structures within a polypeptide. These structures are commonly known as domains, for example, enzymatic domains, extracellular domains, transmembrane domains, pore domains, and cytoplasmic tail domains. Domains are portions of a polypeptide that form a compact unit of the polypeptide and are typically 15 to 350 amino acids long. Exemplary domains include domains with enzymatic activity or ligand binding activity. Typical domains are made up of sections of lesser organization such as stretches of beta-sheet and alpha-helices. “Tertiary structure” refers to the complete three dimensional structure of a polypeptide monomer. “Quaternary structure” refers to the three dimensional structure formed by the noncovalent association of independent tertiary units. A “motif” is a portion of a polypeptide sequence and includes at least two amino acids. A motif may be, for example, 2 to 20, 2 to 15, or 2 to 10 amino acids in length. In some embodiments, a motif includes 3, 4, 5, 6, or 7 sequential amino acids. A domain may be comprised of a series of the same type of motif.

“Recombinant” when used with reference, for example, to a cell, nucleic acid, polynucleotide, protein, or vector, indicates that the cell, nucleic acid, polynucleotide protein, or vector, has been modified by the introduction of a heterologous nucleic acid or protein or the alteration of a native polynucleotide or protein, or that the cell is derived from a cell so modified. Thus, for example, recombinant cells express genes that are not found within the native (non-recombinant) form of the cell or express native genes that are otherwise abnormally expressed, under expressed, or not expressed at all. For example, the term “recombinant DNA molecule” as used herein refers to a DNA molecule which is comprised of segments of DNA joined together by means of molecular biological techniques. The term “recombinant protein” or “recombinant polypeptide” as used herein refers to a protein molecule which is expressed from a recombinant DNA molecule or recombinant polynucleotide.

The term “specificity” as used herein refers to the number of true negatives divided by the number of true negatives plus the number of false positives, where specificity (“spec”) may be within the range of $0 < \text{spec} < 1$. Hence, a method that has both sensitivity and specificity equaling one, or 100%, is preferred.

By “specifically binds,” it is generally meant that an agent or polypeptide binds to a target when it binds to that target more readily than it would bind to a random, unrelated target.

“Sample” or “test sample” as used herein can mean any sample in which the presence and/or level of an activity, a biomarker, target, agent, vector, or molecule, etc., is to be detected or determined. Samples may include liquids, solutions, emulsions, mixtures, or suspensions. Samples may include a medical sample. Samples may include any biological fluid or tissue, such as blood, whole blood, fractions of blood such as plasma and serum, peripheral blood mononuclear cells (PBMCs), muscle, interstitial fluid, sweat, saliva, urine, tears, synovial fluid, bone marrow, cerebrospinal fluid, nasal secretions, sputum, amniotic fluid, bronchioalveolar lavage fluid, gastric lavage, emesis, fecal matter, lung tissue, peripheral blood mononuclear cells, total white blood cells, lymph node cells, spleen cells, tonsil cells, cancer cells, tumor cells, bile, digestive fluid, skin, or combinations thereof. In some embodiments, the sample comprises an aliquot. In other embodiments, the sample comprises a biological fluid. Samples can be obtained by any means known in the art. The sample can be used directly as obtained from a subject or can be pre-treated, such as by filtration, distillation, extraction, concentration, centrifugation, inactivation of interfering components, addition of reagents, and the like, to modify the character of the sample in some manner as discussed herein or otherwise as is known in the art. Samples may be obtained before treatment, before diagnosis, during treatment, after treatment, or after diagnosis, or a combination thereof.

“Subject” as used herein can mean an organism that wants or is in need of the herein described compositions or methods. The subject may be a human or a non-human animal. The subject may be a microorganism. The subject may be a mammal. The mammal may be a primate or a non-primate. The mammal can be a primate such as a human; a non-primate such as, for example, dog, cat, horse, cow, pig, mouse, rat, camel, llama, goat, rabbit, sheep, hamster, and guinea pig; or non-human primate such as, for example, monkey, chimpanzee, gorilla, orangutan, and gibbon. The subject may be of any age or stage of development, such as, for example, an adult, an adolescent, or an infant.

In some embodiments, the subject is human. In some embodiments, the subject has a specific genetic marker.

"Substantially identical" can mean that a first and second amino acid or polynucleotide sequence are at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% over a region of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100 amino acids or nucleotides, respectively.

A "therapeutically effective amount," or "effective dosage," or "effective amount" as used interchangeably herein unless otherwise defined, means a dosage of an agent or drug effective for periods of time necessary, to achieve the desired therapeutic result. An effective dosage may be determined by a person skilled in the art and may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the drug to elicit a desired response in the individual. This term as used herein may also refer to an amount effective at bringing about a desired in vivo effect in a subject. A therapeutically effective amount may be administered in one or more administrations (e.g., the composition may be given as a preventative treatment or therapeutically at any stage of disease progression, before or after symptoms, and the like), applications, or dosages, and is not intended to be limited to a particular formulation, combination, or administration route. It is within the scope of the present disclosure that the drug may be administered at various times during the course of treatment of the subject. The times of administration and dosages used will depend on several factors, such as the goal of treatment (e.g., treating v. preventing), condition of the subject, etc. and can be readily determined by one skilled in the art. A therapeutically effective amount is also one in which any toxic or detrimental effects of substance are outweighed by the therapeutically beneficial effects. A "prophylactically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result. Typically, since a prophylactic dose is used in subjects prior to or at an earlier stage of disease, the prophylactically effective amount will be less than the therapeutically effective amount.

The terms "treat," "treated," or "treating" as used herein refers to a therapeutic wherein the object is to slow down (lessen) an undesired physiological condition, disorder or disease, or to obtain beneficial or desired clinical results. For the purposes of this invention, beneficial or desired clinical results include, but are not limited to, alleviation of symptoms; diminishment of the extent of the condition, disorder or disease; stabilization (i.e., not worsening) of the state of the condition, disorder or disease; delay in onset or slowing of the progression of the condition, disorder or disease; amelioration of the condition, disorder or disease state; and remission (whether partial or total), whether detectable or undetectable, or enhancement or improvement of the condition, disorder or disease. Treatment also includes prolonging survival as compared to expected survival if not receiving treatment. The terms "treat," "treated," or "treating" may include preventing, suppressing, repressing, ameliorating, or completely eliminating the disease. Preventing the disease may involve administering a composition of the present invention to a subject prior to onset of the disease. Suppressing the disease may involve administering a composition of the present invention to a subject after induction of the disease but before its clinical appearance. Repressing or

ameliorating the disease may involve administering a composition of the present invention to a subject after clinical appearance of the disease.

"Variant" as used herein with respect to a polynucleotide means (i) a portion or fragment of a referenced nucleotide sequence; (ii) the complement of a referenced nucleotide sequence or portion thereof; (iii) a polynucleotide that is substantially identical to a referenced polynucleotide or the complement thereof; or (iv) a polynucleotide that hybridizes under stringent conditions to the referenced polynucleotide, complement thereof, or a sequences substantially identical thereto.

A "variant" can further be defined as a peptide or polypeptide that differs in amino acid sequence by the insertion, deletion, or conservative substitution of amino acids, but retain at least one biological activity. Representative examples of "biological activity" include the ability to be bound by a specific antibody or polypeptide or to promote an immune response. Variant can mean a substantially identical sequence. Variant can mean a functional fragment thereof. Variant can also mean multiple copies of a polypeptide. The multiple copies can be in tandem or separated by a linker. Variant can also mean a polypeptide with an amino acid sequence that is substantially identical to a referenced polypeptide with an amino acid sequence that retains at least one biological activity. A conservative substitution of an amino acid, i.e., replacing an amino acid with a different amino acid of similar properties (e.g., hydrophilicity, degree and distribution of charged regions) is recognized in the art as typically involving a minor change. These minor changes can be identified, in part, by considering the hydropathic index of amino acids. See Kyte et al., *J. Mol. Biol.* 1982, 157, 105-132. The hydropathic index of an amino acid is based on a consideration of its hydrophobicity and charge. It is known in the art that amino acids of similar hydropathic indexes can be substituted and still retain protein function. In one aspect, amino acids having hydropathic indices of ± 2 are substituted. The hydrophobicity of amino acids can also be used to reveal substitutions that would result in polypeptides retaining biological function. A consideration of the hydrophilicity of amino acids in the context of a polypeptide permits calculation of the greatest local average hydrophilicity of that polypeptide, a useful measure that has been reported to correlate well with antigenicity and immunogenicity, as discussed in U.S. Pat. No. 4,554,101, which is fully incorporated herein by reference. Substitution of amino acids having similar hydrophilicity values can result in polypeptides retaining biological activity, for example immunogenicity, as is understood in the art. Substitutions can be performed with amino acids having hydrophilicity values within ± 2 of each other. Both the hydrophobicity index and the hydrophilicity value of amino acids are influenced by the particular side chain of that amino acid. Consistent with that observation, amino acid substitutions that are compatible with biological function are understood to depend on the relative similarity of the amino acids, and particularly the side chains of those amino acids, as revealed by the hydrophobicity, hydrophilicity, charge, size, and other properties. A variant can be a polynucleotide sequence that is substantially identical over the full length of the full gene sequence or a fragment thereof. The polynucleotide sequence can be 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical over the full length of the gene sequence or a fragment thereof. A variant can be an amino acid sequence that is substantially identical over the full length of the amino acid sequence or fragment thereof.

11

The amino acid sequence can be 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical over the full length of the amino acid sequence or a fragment thereof. In some embodiments, variants include homologues. Homologues may be polynucleotides or polypeptides or genes inherited in two species by a common ancestor.

2. TYROSINE KINASE

A tyrosine kinase is an enzyme that can transfer a gamma (terminal) phosphate group from ATP to a polypeptide in a cell. The phosphate group is attached to the amino acid tyrosine on the polypeptide. The tyrosine kinase may phosphorylate one or more tyrosine residues on a polypeptide. The phosphorylation of the tyrosine on the polypeptide can cause a change in the function of the polypeptide. Tyrosine kinases are a subgroup of the larger class of protein kinases that attach phosphate groups to other amino acids (such as serine and threonine). Phosphorylation of proteins by kinases is one mechanism in communicating signals within a cell (signal transduction) and regulating cellular activity, such as cell division.

The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is a member of the ErbB family of receptors, which is a subfamily of four closely related receptor tyrosine kinases. The ErbB family of receptors includes EGFR (ErbB-1; HER1), HER2/neu (ErbB-2), HER3 (ErbB-3), and HER4 (ErbB-4). EGFR is a transmembrane protein that is a receptor for members of the epidermal growth factor family (EGF family) of extracellular protein ligands. EGFR is activated by binding of its specific ligands, the ligands including epidermal growth factor (EGF) and transforming growth factor α (TGF α). Upon activation by its ligands, EGFR may transition from an inactive monomeric form to an active homodimer. In addition to forming homodimers after ligand binding, EGFR may pair with another member of the ErbB receptor family, such as ErbB2/Her2/neu, to create an activated heterodimer. EGFR dimerization may stimulate its intrinsic intracellular protein-tyrosine kinase activity. As a result, autophosphorylation of several tyrosine residues in the C-terminal domain of EGFR may occur. These tyrosine residues may include Y992, Y1045, Y1068, Y1148 and Y1173. The autophosphorylation of EGFR may elicit downstream activation and signaling by several other polypeptides that associate with the phosphorylated tyrosines through their own phosphotyrosine-binding SH2 domains. These downstream signaling polypeptides may initiate several signal transduction cascades, such as the MAPK, Akt and JNK pathways. The signal transduction cascades may lead to cellular activities such as DNA synthesis, cell proliferation, cell migration, and cell adhesion. The kinase domain of EGFR may also cross-phosphorylate tyrosine residues of other receptors it is aggregated with, and EGFR can itself be cross-phosphorylated and activated by a kinase domain of a receptor it is aggregated with.

Mutations affecting EGFR expression or activity may result in cancer. For example, mutations leading to over-expression of EGFR are associated with the development of a wide variety of cancers. Over-expression of EGFR or constant activation of EGFR may produce uncontrolled cell division.

a. Tyrosine Kinase Inhibitors

A tyrosine kinase inhibitor (TKI) inhibits the activity or expression of a tyrosine kinase. A tyrosine kinase inhibitor may include an antibody, a polynucleotide such as interfer-

12

ing RNA, a small molecule, or a combination thereof. In some embodiments, the tyrosine kinase inhibitor comprises an antibody. In some embodiments, the tyrosine kinase inhibitor comprises a small molecule. The tyrosine kinase inhibitor may be specific for a particular tyrosine kinase, or for a particular family or subfamily of tyrosine kinases. In some embodiments, the tyrosine kinase inhibitor is specific for EGFR. Such inhibitors may be referred to as "EGFR inhibitors." Antibody EGFR inhibitors include, for example, cetuximab and panitumumab. Small molecule EGFR inhibitors include, for example, lapatinib (a mixed EGFR and ERBB2 inhibitor), mereletinib (osimertinib), gefitinib, icotinib, erlotinib, afatinib, and brigatinib. In some embodiments, the EGFR inhibitor comprises lapatinib. The EGFR inhibitor may bind and inhibit the kinase domain of the EGFR. Without kinase activity, the EGFR may not be able to activate itself or induce downstream activation and signaling.

3. ANTI-RESISTANCE AGENT

Further provided herein is an anti-resistance agent. The anti-resistance agent may reduce or prevent resistance of a cancer to a tyrosine kinase inhibitor. The anti-resistance agent may be, for example, an antibody, a polynucleotide, a small molecule, or a combination thereof. The anti-resistance agent may cause target alteration, increase or decrease ligand production or availability, increase or decrease downstream pathway activation, or activate or inhibit an alternative pathway, or a combination thereof, to reduce or prevent resistance of a cancer to a tyrosine kinase inhibitor. Acquired drug resistance to the tyrosine kinase inhibitor may be decreased or prevented following administration of the anti-resistance agent. Tyrosine kinase inhibitor resistance may be decreased at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, at least 10-fold, at least 11-fold, at least 12-fold, at least 13-fold, at least 14-fold, at least 15-fold, at least 16-fold, at least 17-fold, at least 18-fold, at least 19-fold, or at least 20-fold. In some embodiments, tyrosine kinase inhibitor resistance is decreased 2-fold to 10-fold. Tyrosine kinase inhibitor activity may be increased at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, at least 10-fold, at least 11-fold, at least 12-fold, at least 13-fold, at least 14-fold, at least 15-fold, at least 16-fold, at least 17-fold, at least 18-fold, at least 19-fold, or at least 20-fold. In some embodiments, tyrosine kinase inhibitor activity is increased 2-fold to 10-fold. Anti-resistance agents may include CYP51A1 inhibitors and agonists of miRNA-764 (SEQ ID NO: 4).

a. CYP51A1 Inhibitor

A CYP51A1 inhibitor inhibits the activity or expression of CYP51A1 (lanosterol 14 α -demethylase; Cytochrome P450, Family 51, Subfamily A, Polypeptide 1). CYP51A1 is a cytochrome P450 enzyme that is involved in the conversion of lanosterol to 4,4-dimethylcholesta-8(9),14,24-trien-3 β -ol, which is a step in the biosynthesis of sterols. In particular, CYP51A1 catalyzes the removal of the C-14 α -methyl group from lanosterol. This demethylation step is an initial checkpoint in the transformation of lanosterol to other sterols that are widely used within the cell. CYP51A1 may comprise a polypeptide having an amino acid sequence of SEQ ID NO: 1. CYP51A1 may be encoded by gene having a polynucleotide sequence of SEQ ID NO: 2, which may be

transcribed to an mRNA having a polynucleotide sequence of SEQ ID NO: 3. CYP51A1 inhibitors include, for example, ketoconazole.

b. Agonist of miRNA-764

Further provided herein are agonists of miRNA-764 (SEQ ID NO: 4). Without being bound by theory, it is possible that miRNA-764 (SEQ ID NO: 4) may regulate CYP51A1. miRNA-764 (SEQ ID NO: 4) may regulate CYP51A1 by binding to the 3'-UTR of the CYP51A1 mRNA (SEQ ID NO: 3) and represses translation of the CYP51A1 mRNA. Agonists of miRNA-764 (SEQ ID NO: 4) increase the level or activity of miRNA-764 (SEQ ID NO: 4). In some embodiments, an agonist of miRNA-764 (SEQ ID NO: 4) comprises a polynucleotide of SEQ ID NO: 4.

4. ADDITIONAL CANCER THERAPIES

In some embodiments, the compositions and methods detailed herein may be used in combination with other cancer therapies. These additional cancer therapies may be administered to a subject at the same time, before, or after the anti-resistance agent or tyrosine kinase inhibitor. Additional cancer therapies may include, for example, chemotherapy, radiation, and surgery.

Chemotherapy uses one or more chemotherapeutic agents to kill highly proliferating cells. A chemotherapeutic agent includes a compound or composition that is administered in the treatment of cancer or other hyperproliferative disease. Chemotherapeutic agents may be categorized by their mode of activity within a cell, for example, whether and at what stage they affect the cell cycle. Alternatively, a chemotherapeutic agent may be characterized based on its ability to directly cross-link DNA, to intercalate into DNA, or to induce chromosomal and mitotic aberrations by affecting nucleic acid synthesis. Categories of chemotherapeutic agents include, for example, alkylating agents, antimetabolites, antitumor antibiotics, mitotic inhibitors, and nitrosoureas. Specific chemotherapeutic agents may include, for example, cyclophosphamide, doxorubicin, daunorubicin, vinblastine, vincristine, bleomycin, etoposide, topotecan, irinotecan, taxotere, taxol, 5-fluorouracil, methotrexate, gemcitabine, cisplatin, carboplatin, and chlorambucil, and an agonist of any of the above compounds.

Radiotherapy, also called radiation therapy, is the treatment of cancer and other diseases with ionizing radiation. Ionizing radiation deposits energy that injures or destroys cells in the area being treated by damaging their genetic material, making it impossible for these cells to continue to grow. Although radiation damages both cancer cells and normal cells, normal cells are able to repair and function properly. Radiotherapy may be used to treat localized solid tumors, such as cancers of the skin, tongue, larynx, brain, breast, or cervix. It can also be used to treat leukemia and lymphoma (cancers of the blood-forming cells and lymphatic system, respectively).

Radiation therapy may include, for example, the use of γ -rays, X-rays, and/or the directed delivery of radioisotopes to tumor cells. Other forms of DNA damaging factors are also contemplated such as microwaves, proton beam irradiation (U.S. Pat. Nos. 5,760,395 and 4,870,287) and UV-irradiation. Radiation therapy may cause a broad range of damage on DNA, on the precursors of DNA, on the replication and repair of DNA, on the assembly and maintenance of chromosomes, or a combination thereof. Dosage ranges for X-rays range from daily doses of 50 to 200 roentgens for prolonged periods of time (3 to 4 weeks), to single doses of 2000 to 6000 roentgens. Dosage ranges for radioisotopes

vary widely, and depend on the half-life of the isotope, the strength and type of radiation emitted, and the uptake by the neoplastic cells. Radiotherapy may also include the use of radiolabeled antibodies to deliver doses of radiation directly to the cancer site (radioimmunotherapy). Once injected into the body, the antibodies may actively seek out the cancer cells, which are destroyed by the cell-killing (cytotoxic) action of the radiation. This approach can minimize the risk of radiation damage to healthy cells.

Surgery may include full or partial removal of a tumor or cancerous tissue. Surgery may also include removal of any surrounding tissue. Surgery may include removal of any tissue anticipated to be at risk of cancer, such as from spreading or metastasis of cancer to the tissue.

5. PHARMACEUTICAL COMPOSITIONS

Further provided herein are pharmaceutical compositions comprising one or more anti-resistance agents. The pharmaceutical compositions may further include one or more tyrosine kinase inhibitors. Also provided herein are pharmaceutical compositions comprising one or more tyrosine kinase inhibitors. The pharmaceutical compositions may be formulated in accordance with standard techniques well known to those skilled in the pharmaceutical art. The pharmaceutical composition may comprise the anti-resistance agent and/or tyrosine kinase inhibitor and a pharmaceutically acceptable carrier. The term "pharmaceutically acceptable carrier," as used herein, means a non-toxic, inert solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type.

The route by which the disclosed anti-resistance agents and/or tyrosine kinase inhibitors are administered and the form of the composition will dictate the type of carrier to be used. The pharmaceutical composition may be in a variety of forms, suitable, for example, for systemic administration (e.g., oral, rectal, sublingual, buccal, implants, intranasal, intravaginal, transdermal, intravenous, intraarterial, intratumoral, intraperitoneal, or parenteral) or topical administration (e.g., dermal, pulmonary, nasal, aural, ocular, liposome delivery systems, or iontophoresis). Techniques and formulations may generally be found in "Remington's Pharmaceutical Sciences," (Meade Publishing Co., Easton, Pa.). Pharmaceutical compositions must typically be sterile and stable under the conditions of manufacture and storage. All carriers are optional in the compositions.

Pharmaceutically acceptable carriers include, for example, diluents, lubricants, binders, disintegrants, colorants, flavors, sweeteners, antioxidants, preservatives, glidants, solvents, suspending agents, wetting agents, surfactants, emollients, propellants, humectants, powders, pH adjusting agents, and combinations thereof.

Suitable diluents include, for example, sugars such as glucose, lactose, dextrose, and sucrose; diols such as propylene glycol; calcium carbonate; sodium carbonate; sugar alcohols, such as glycerin; mannitol; sorbitol; cellulose; starch; and gelatin. The amount of diluent(s) in a systemic or topical composition may typically be about 50 to about 90%.

Suitable lubricants include, for example, silica, talc, stearic acid and its magnesium salts and calcium salts, calcium sulfate; and liquid lubricants such as polyethylene glycol and vegetable oils such as peanut oil, cottonseed oil, sesame oil, olive oil, corn oil, and oil of theobroma. The amount of lubricant(s) in a systemic or topical composition may typically be about 5 to about 10%.

Suitable binders include, for example, polyvinyl pyrrolidone; magnesium aluminum silicate; starches such as corn

starch and potato starch; gelatin; tragacanth; sucrose; and cellulose and its derivatives, such as sodium carboxymethylcellulose, ethyl cellulose, methylcellulose, microcrystalline cellulose, and hydroxypropyl methylcellulose. The amount of binder(s) in a systemic composition may typically be about 5 to about 50%.

Suitable disintegrants include, for example, agar, alginic acid and the sodium salt thereof, effervescent mixtures, croscarmellose, crospovidone, sodium carboxymethyl starch, sodium starch glycolate, clays, and ion exchange resins. The amount of disintegrant(s) in a systemic or topical composition may typically be about 0.1 to about 10%.

Suitable colorants include, for example, a colorant such as an FD&C dye. When used, the amount of colorant in a systemic or topical composition may typically be about 0.005 to about 0.1%.

Suitable flavors include, for example, menthol, peppermint, and fruit flavors. The amount of flavor(s), when used, in a systemic or topical composition may typically be about 0.1 to about 1.0%.

Suitable sweeteners include, for example, aspartame and saccharin, or a combination thereof. The amount of sweetener(s) in a systemic or topical composition may typically be about 0.001 to about 1%.

Suitable antioxidants include, for example, butylated hydroxyanisole ("BHA"), butylated hydroxytoluene ("BHT"), and vitamin E. The amount of antioxidant(s) in a systemic or topical composition may typically be about 0.1 to about 5%.

Suitable preservatives include, for example, benzalkonium chloride, methyl paraben, and sodium benzoate. The amount of preservative(s) in a systemic or topical composition may typically be about 0.01 to about 5%.

Suitable glidants include, for example, silicon dioxide. The amount of glidant(s) in a systemic or topical composition may typically be about 1 to about 5%.

Suitable solvents include, for example, water, isotonic saline, ethyl oleate, glycerine, castor oils, hydroxylated castor oils, alcohols such as ethanol or isopropanol, methylene chloride, ethylene glycol monoethyl ether, diethylene glycol monobutyl ether, diethylene glycol monoethyl ether, dimethylsulfoxide, dimethyl formamide, tetrahydrofuran, and phosphate buffer solutions, and combinations thereof. The amount of solvent(s) in a systemic or topical composition is typically from about 0 to about 100%, or 0% to about 95%.

Suitable suspending agents include, for example, AVICEL RC-591 (from FMC Corporation of Philadelphia, Pa.) and sodium alginate. The amount of suspending agent(s) in a systemic or topical composition may typically be about 1 to about 8%.

Suitable surfactants include, for example, lecithin, Polysorbate 80, and sodium lauryl sulfate, and the TWEENS from Atlas Powder Company of Wilmington, Del. Suitable surfactants include those disclosed in the C.T.F.A. Cosmetic Ingredient Handbook, 1992, pp. 587-592; Remington's Pharmaceutical Sciences, 15th Ed. 1975, pp. 335-337; and McCutcheon's Volume 1, Emulsifiers & Detergents, 1994, North American Edition, pp. 236-239. The amount of surfactant(s) in the systemic or topical composition may typically be about 0.1% to about 5%.

Suitable emollients include, for example, stearyl alcohol, glyceryl monoricinoleate, glyceryl monostearate, propane-1,2-diol, butane-1,3-diol, mink oil, cetyl alcohol, isopropyl isostearate, stearic acid, isobutyl palmitate, isocetyl stearate, oleyl alcohol, isopropyl laurate, hexyl laurate, decyl oleate, octadecan-2-ol, isocetyl alcohol, cetyl palmitate, di-n-butyl

sebacate, isopropyl myristate, isopropyl palmitate, isopropyl stearate, butyl stearate, polyethylene glycol, triethylene glycol, lanolin, sesame oil, coconut oil, arachis oil, castor oil, acetylated lanolin alcohols, petroleum, mineral oil, butyl myristate, isostearic acid, palmitic acid, isopropyl linoleate, lauryl lactate, myristyl lactate, decyl oleate, myristyl myristate, and combinations thereof. Specific emollients for skin include stearyl alcohol and polydimethylsiloxane. The amount of emollient(s) in a skin-based topical composition may typically be about 5% to about 95%.

Suitable propellants include, for example, propane, butane, isobutane, dimethyl ether, carbon dioxide, nitrous oxide, and combinations thereof. The amount of propellant in a topical composition may be about 0% to about 95%.

Suitable humectants include, for example, glycerin, sorbitol, sodium 2-pyrrolidone-5-carboxylate, soluble collagen, dibutyl phthalate, gelatin, and combinations thereof. The amount of humectant in a composition may be about 0% to about 95%.

Suitable powders include, for example, beta-cyclodextrins, hydroxypropyl cyclodextrins, chalk, talc, fullers earth, kaolin, starch, gums, colloidal silicon dioxide, sodium polyacrylate, tetra alkyl ammonium smectites, trialkyl aryl ammonium smectites, chemically-modified magnesium aluminum silicate, organically-modified Montmorillonite clay, hydrated aluminum silicate, fumed silica, carboxyvinyl polymer, sodium carboxymethyl cellulose, ethylene glycol monostearate, and combinations thereof. The amount of powder(s) in a composition may typically be 0% to 95%.

Suitable pH adjusting additives include, for example, HCl or NaOH in amounts sufficient to adjust the pH of a topical pharmaceutical composition.

In some embodiments, the pharmaceutically acceptable carrier is a sugar such as lactose, glucose, and sucrose. In some embodiments, the pharmaceutically acceptable carrier is a starch such as, for example, corn starch and potato starch. In some embodiments, the pharmaceutically acceptable carrier is cellulose and its derivatives such as, but not limited to, sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate. In some embodiments, the pharmaceutically acceptable carrier is powdered tragacanth, malt, gelatin, or talc. In some embodiments, the pharmaceutically acceptable carrier is an excipient such as, but not limited to, cocoa butter and suppository waxes. In some embodiments, the pharmaceutically acceptable carrier is oil such as, but not limited to, peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil. In some embodiments, the pharmaceutically acceptable carrier is a glycol, such as propylene glycol. In some embodiments, the pharmaceutically acceptable carrier is an ester such as, but not limited to, ethyl oleate and ethyl laurate. In some embodiments, the pharmaceutically acceptable carrier is an agar. In some embodiments, the pharmaceutically acceptable carrier is a buffering agent such as, but not limited to, magnesium hydroxide and aluminum hydroxide. In some embodiments, the pharmaceutically acceptable carrier is alginic acid, pyrogen-free water, isotonic saline, Ringer's solution, ethyl alcohol, or a phosphate buffer solution. In some embodiments, the pharmaceutically acceptable carrier is a non-toxic compatible lubricant such as, but not limited to, sodium lauryl sulfate and magnesium stearate.

Compositions for oral administration can have various dosage forms. For example, solid forms include tablets, capsules, granules, and bulk powders. Tablets can be compressed, tablet triturates, enteric-coated, sugar-coated, film-coated, or multiple-compressed. Tablets typically include an active component, and a carrier comprising ingredients

selected from diluents, lubricants, binders, disintegrants, colorants, flavors, sweeteners, glidants, and combinations thereof. Capsules (including implants, time release, and sustained release formulations) typically include a compound, and a carrier including one or more diluents disclosed above in a capsule comprising gelatin. Granules typically comprise a compound, and preferably glidants such as silicon dioxide to improve flow characteristics. Implants can be of the biodegradable or the non-biodegradable type.

Compositions for oral administration can have solid forms. Solid oral compositions may be coated by conventional methods, typically with pH or time-dependent coatings, such that a compound is released in the gastrointestinal tract in the vicinity of the desired application, or at various points and times to extend the desired action. The coatings typically include one or more components selected from the group consisting of cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropyl methyl cellulose phthalate, ethyl cellulose, EUDRAGIT® coatings (available from Evonik Industries of Essen, Germany), waxes, and shellac.

Compositions for oral administration can have liquid forms. For example, suitable liquid forms include aqueous solutions, emulsions, suspensions, solutions reconstituted from non-effervescent granules, suspensions reconstituted from non-effervescent granules, effervescent preparations reconstituted from effervescent granules, elixirs, tinctures, syrups, and the like. Liquid orally administered compositions typically include a compound and a carrier, namely, a carrier selected from diluents, colorants, flavors, sweeteners, preservatives, solvents, suspending agents, and surfactants. Peroral liquid compositions preferably include one or more ingredients selected from colorants, flavors, and sweeteners.

Compositions for topical administration can be applied locally to the skin and may be in any form including solids, solutions, oils, creams, ointments, gels, lotions, shampoos, leave-on and rinse-out hair conditioners, milks, cleansers, moisturizers, sprays, skin patches, and the like. The carrier of the topical composition preferably aids penetration of the compound into the skin. In the topical compositions, the carrier includes a topical carrier. Suitable topical carriers can include one or more ingredients selected from phosphate buffered saline, isotonic water, deionized water, monofunctional alcohols, symmetrical alcohols, aloe vera gel, allantoin, glycerin, vitamin A and E oils, mineral oil, propylene glycol, PPG-2 myristyl propionate, dimethyl isosorbide, castor oil, combinations thereof, and the like. More particularly, carriers for skin applications may include propylene glycol, dimethyl isosorbide, and water, and even more particularly, phosphate buffered saline, isotonic water, deionized water, monofunctional alcohols, and symmetrical alcohols. The carrier of a topical composition may further include one or more ingredients selected from emollients, propellants, solvents, humectants, thickeners, powders, fragrances, pigments, and preservatives, all of which are optional.

Although the amounts of components in the compositions may vary depending on the type of composition prepared, in general, systemic compositions may include 0.01% to 50% of a compound and 50% to 99.99% of one or more carriers. Compositions for parenteral administration may typically include 0.1% to 10% of a compound and 90% to 99.9% of one or more carriers. Oral dosage forms may include, for example, at least about 5%, or about 25% to about 50% of a compound. The oral dosage compositions may include about 50% to about 95% of carriers, or from about 50% to about 75% of carriers. The amount of the carrier employed

in conjunction with a disclosed compound is sufficient to provide a practical quantity of composition for administration per unit dose of the compound. Techniques and compositions for making dosage forms useful in the methods of this invention are described in the following references: Modern Pharmaceutics, Chapters 9 and 10, Banker & Rhodes, eds. (1979); Lieberman et al., Pharmaceutical Dosage Forms: Tablets (1981); and Ansel, Introduction to Pharmaceutical Dosage Forms, 2nd Ed., (1976).

6. ADMINISTRATION

The anti-resistance agents and/or tyrosine kinase inhibitors as detailed herein, or the pharmaceutical compositions comprising the same, may be administered to a subject. The anti-resistance agents and/or tyrosine kinase inhibitors as detailed herein can be formulated into a composition and administered in dosages and by techniques well known to those skilled in the medical arts taking into consideration such factors as the age, sex, weight, and condition of the particular subject, and the route of administration.

The anti-resistance agents and/or tyrosine kinase inhibitors can be administered prophylactically or therapeutically. In prophylactic administration, the anti-resistance agents and/or tyrosine kinase inhibitors can be administered in an amount sufficient to induce a response. In therapeutic applications, the anti-resistance agents and/or tyrosine kinase inhibitors are administered to a subject in need thereof in an amount sufficient to elicit a therapeutic effect. The anti-resistance agents and/or tyrosine kinase inhibitors may be administered in a therapeutically effective amount.

For example, a therapeutically effective amount of an anti-resistance agent and/or tyrosine kinase inhibitor or a pharmaceutically acceptable salt thereof, may be about 1 mg/kg to about 1000 mg/kg, about 5 mg/kg to about 950 mg/kg, about 10 mg/kg to about 900 mg/kg, about 15 mg/kg to about 850 mg/kg, about 20 mg/kg to about 800 mg/kg, about 25 mg/kg to about 750 mg/kg, about 30 mg/kg to about 700 mg/kg, about 35 mg/kg to about 650 mg/kg, about 40 mg/kg to about 600 mg/kg, about 45 mg/kg to about 550 mg/kg, about 50 mg/kg to about 500 mg/kg, about 55 mg/kg to about 450 mg/kg, about 60 mg/kg to about 400 mg/kg, about 65 mg/kg to about 350 mg/kg, about 70 mg/kg to about 300 mg/kg, about 75 mg/kg to about 250 mg/kg, about 80 mg/kg to about 200 mg/kg, about 85 mg/kg to about 150 mg/kg, and about 90 mg/kg to about 100 mg/kg.

The anti-resistance agents and/or tyrosine kinase inhibitors can be administered by methods well known in the art as described in Donnelly et al. (Ann. Rev. Immunol. 1997, 15, 617-648); Feigner et al. (U.S. Pat. No. 5,580,859, issued Dec. 3, 1996); Feigner (U.S. Pat. No. 5,703,055, issued Dec. 30, 1997); and Carson et al. (U.S. Pat. No. 5,679,647, issued Oct. 21, 1997), the contents of all of which are incorporated herein by reference in their entirety. The anti-resistance agents and/or tyrosine kinase inhibitors can be complexed to particles or beads that can be administered to an individual, for example, using a vaccine gun. One skilled in the art would know that the choice of a pharmaceutically acceptable carrier, including a physiologically acceptable compound, depends, for example, on the route of administration.

The anti-resistance agents and/or tyrosine kinase inhibitors can be delivered via a variety of routes. Typical delivery routes include parenteral administration, e.g., intradermal, intramuscular or subcutaneous delivery. Other routes include oral administration, intranasal, intravaginal, transdermal, intravenous, intraarterial, intratumoral, intraperitoneal, and epidermal routes. In some embodiments, the

anti-resistance agents and/or tyrosine kinase inhibitors are administered intravenously, intraarterially, or intraperitoneally to the subject.

The anti-resistance agents and/or tyrosine kinase inhibitors can be a liquid preparation such as a suspension, syrup, or elixir. The anti-resistance agents and/or tyrosine kinase inhibitors can be incorporated into liposomes, microspheres, or other polymer matrices (such as by a method described in Feigner et al., U.S. Pat. No. 5,703,055; Gregoriadis, *Liposome Technology*, Vols. I to III (2nd ed. 1993), the contents of which are incorporated herein by reference in their entirety). Liposomes can consist of phospholipids or other lipids, and can be nontoxic, physiologically acceptable and metabolizable carriers that are relatively simple to make and administer.

The anti-resistance agents and/or tyrosine kinase inhibitors may be used as a vaccine. The vaccine can be administered via electroporation, such as by a method described in U.S. Pat. No. 7,664,545, the contents of which are incorporated herein by reference. The electroporation can be by a method and/or apparatus described in U.S. Pat. Nos. 6,302,874; 5,676,646; 6,241,701; 6,233,482; 6,216,034; 6,208,893; 6,192,270; 6,181,964; 6,150,148; 6,120,493; 6,096,020; 6,068,650; and 5,702,359, the contents of which are incorporated herein by reference in their entirety. The electroporation can be carried out via a minimally invasive device.

In some embodiments, the anti-resistance agents and/or tyrosine kinase inhibitors are administered in a controlled release formulation. The anti-resistance agents and/or tyrosine kinase inhibitors may be released into the circulation, for example. In some embodiments, the anti-resistance agents and/or tyrosine kinase inhibitors may be released over a period of at least about 1 day, at least about 2 days, at least about 3 days, at least about 4 days, at least about 5 days, at least about 6 days, at least about 7 days, at least about 1 week, at least about 1.5 weeks, at least about 2 weeks, at least about 2.5 weeks, at least about 3.5 weeks, at least about 4 weeks, or at least about 1 month.

7. METHODS

a. Methods of Treating Cancer in a Subject

Provided herein are methods of treating cancer in a subject. The methods may include administering to the subject a tyrosine kinase inhibitor and an anti-resistance agent. In some embodiments, the tyrosine kinase inhibitor and the anti-resistance agent are co-administered to the subject. In some embodiments, the tyrosine kinase inhibitor is administered to the subject prior to the anti-resistance agent. In some embodiments, the anti-resistance agent is administered to the subject prior to the tyrosine kinase inhibitor. In some embodiments, the cancer is a tyrosine kinase inhibitor-resistant cancer. In some embodiments, acquired drug resistance to the tyrosine kinase inhibitor is decreased or prevented. In some embodiments, the activity of the tyrosine kinase inhibitor is increased. Inhibition of CYP51A1 or upregulation of miR-764 (SEQ ID NO: 4) can be used as therapeutics for the treatment of lapatinib-resistant lung cancers.

b. Method of Treating Cancer in a Subject Undergoing Treatment with a Tyrosine Kinase Inhibitor

Provided herein are methods of treating cancer in a subject undergoing treatment with a tyrosine kinase inhibitor. The methods may include administering to the subject an anti-resistance agent. In some embodiments, the cancer is a tyrosine kinase inhibitor-resistant cancer. In some embodi-

ments, acquired drug resistance to the tyrosine kinase inhibitor is decreased or prevented. In some embodiments, the activity of the tyrosine kinase inhibitor is increased.

c. Method for Preventing Drug Resistance or Enhancing the Therapeutic Efficacy of a Tyrosine Kinase Inhibitor

Provided herein are methods for preventing drug resistance or enhancing the therapeutic efficacy of a tyrosine kinase inhibitor in a subject having cancer and undergoing treatment with the tyrosine kinase inhibitor. The methods may include administering to the subject a pharmaceutical composition comprising an anti-resistance agent in an amount effective to attenuate resistance to the tyrosine kinase inhibitor. In some embodiments, acquired drug resistance to the tyrosine kinase inhibitor is decreased or prevented. In some embodiments, the activity of the tyrosine kinase inhibitor is increased.

d. Method of Sensitizing a Tyrosine Kinase Inhibitor-Resistant Cancer

Provided herein are methods of sensitizing a tyrosine kinase inhibitor-resistant cancer in a subject to the tyrosine kinase inhibitor. The methods may include administering to the subject an anti-resistance agent. In some embodiments, acquired drug resistance to the tyrosine kinase inhibitor is decreased or prevented. In some embodiments, the activity of the tyrosine kinase inhibitor is increased. In some embodiments, ketoconazole (a CYP51A1 inhibitor) can be used to sensitize drug resistant cancer cells, and a combination of lapatinib and ketoconazole may be used to prevent acquisition of EGFR-TKI resistance.

8. EXAMPLES

Example 1

Polymeric Scaffold

We found that a polymeric nanofibrous scaffold platform allows growth of three-dimensional (3D) tumor-like aggregates (referred to as tumoroids), which resemble in vivo tumors. As detailed in the Examples below, tumoroids exhibited better drug resistance compared to two-dimensional (2D) cultures that lack ability to mimic the environment of the tumor microenvironment. 3D scaffold may be used to elucidate EGFR TKI resistance mechanisms and help design more efficient treatment strategies to block resistance.

Example 2

Establishment of a Multi-Drug Resistant Cell Lines

To investigate drug resistance to EGFR TKIs, we developed lapatinib resistant human lung cancer cell lines as model for de novo drug resistance. To derive drug resistant (DR) cells, H1975 human lung cancer cells, that carry L858R and T790M point mutations in exons 20 and 21 of EGFR, were grown in a static concentration of lapatinib for up to 30 days. We also developed EGFR TKI resistant H1650 and H1299 human lung cancer cell lines to confirm any potential findings in cell lines with different EGFR mutations, thereby enhancing the reproducibility and relevance of the work. The drug sensitivity of the parental and DR cells on both the monolayer and the 3D scaffold were determined by testing a panel of standard-of-care chemotherapeutics along with EGFR TKIs.

Drug sensitivity in parental- and DR-cell lines were determined. Cells were treated in triplicates with indicated

21

concentrations of the identified drug for 72 hours in mono-layer cultures and for 48 hours in scaffold cultures. For cells grown on the scaffold, drugs were added on day 3, as compared to 24 hours for monolayer. Cell viability was determined using Cell Titer Glo assay (Promega). Results are shown in FIG. 2A. Average luminescence as a percentage of control in lapatinib treated cultures on the monolayer (Blue) and the scaffold (Red) is shown. Experiments were repeated at least two times. Graphs and statistical analysis were derived using GraphPad Prism software. Shown in FIG. 2B are images of the H1975 cell line grown on 3D fibrous scaffold (100×).

Example 3

Analysis of Drug-Resistant Versus Parental Cell Lines

To determine the mechanism of resistance, mass spectroscopy was used to determine the relative levels of certain key proteins being expressed in the H1975 and lapatinib DR-H1975 cell lines. The proteomics data collected using mass spec is served as a guide for future experimentation, and all results of intriguing proteins were confirmed and validated in the EGFR TKI resistant models using other methods, including western blotting and mRNA transcript analysis. We also performed a miRNA array to determine relative levels of key miRNAs being expressed in H1975 and lapatinib DR-H1975 cell lines. miRNA transcript analysis was used to validate this data.

A comparison of the drug sensitivity showed that parental cells were at least 3-fold more sensitive to the EGFR TKIs compared to the DR cells. The sensitivity to EGFR TKIs was further decreased when DR cells were cultured on our fibrous 3D scaffold. Furthermore, qPCR analysis showed upregulation of certain cancer stem cell markers, such as OCT-4 and Nanog, when the cells were grown on the 3D scaffold. This may explain the increased resistance seen when the cells are grown on the 3D scaffold. EGFR TKI resistant cells were also resistant to other anti-cancer agents, such as taxol and gemcitabine. Data mining the significantly differentially expressed proteins list generated by the mass spectroscopic analysis revealed that the protein expression is skewed in lapatinib DR-H1975 cell line as compared to the H1975 cell line. Proteins involved in all aspects of homeostasis including metabolism, biosynthesis, and oxidative regulation were significantly up regulated in the lapatinib resistant cell line. The protein CYP51A1, which is directly involved with cholesterol synthesis, was significantly upregulated in the DR-H1975 cells compared to the parental cells. Western blotting confirmed the upregulation of CYP51A1 in lapatinib resistant cell lines. A CYP51A1 inhibitor, ketoconazole, not only inhibited p-EGFR in the H1650-DR cells, but also alleviated development of lapatinib resistant in parental H1650 cells.

The miRNA array revealed down-regulation of miRNA-764 (SEQ ID NO: 4), which miR Walk 2.0 software has predicted will bind to the 3'-UTR of CYP51A1. This may explain the up-regulation of CYP51A1, as binding of miRNA-764 (SEQ ID NO: 4) to the 3'-UTR of CYP51A1 would repress translation of the mRNA.

Drug-resistant cells (DR) were compared to parental cell lines. 500,000 H1650 cells were plated in 1 well of a 6-well plate and treated with the indicated drugs at the time of plating. They were allowed to grow for 72 hours. Microscopy pictures were taken using bright field microscopy at 100×, and results are shown in FIG. 3A.

22

Cells were treated with lapatinib or ketoconazole for 48 hours. The expression of cleaved EGFR, p-EGFR, CYP51A1 were examined using western blotting of the whole cell lysates. β -Actin was included as a loading control. Results are shown in FIG. 3B. Ketoconazole induced lowering of EGFR downstream signaling. Densitometry of western blot bands was performed using ImageJ software, and results are shown in FIG. 3C.

Selected proteins upregulated in lapatinib-resistant H1975 lung cancers cells were compared to the parental cell line. Whole cell lysate for each cell line was run in duplicate. Peptides for each sample were labeled using ITRAQ labeling kit. Data was collected using the Q Exactive Plus mass spectrometer and analyzed first using MaxQuant proteomics software and next uploaded into Scaffold for statistical analysis. Identified proteins were first subjected to a mann-whitney u-test to look for significant differences in protein abundance. Protein abundance was measured by the average intensities between replicates. Proteins that were identified to have a p-value of $p \leq 0.05$ were further analyzed to characterize the fold change difference between the groups. Results are shown in TABLE 1.

TABLE 1

Selected proteins upregulated in lapatinib resistant H1975 lung cancers cells compared to the parental cell line.		
Altered Proteins	Fold Change Ratio	T-Test Analysis
CYP51A1	2.01	0.021
YWHAH	1.74	0.0032
CPT1A	1.4	0.021
MIC60	1.21	$p < 0.0001$
MAPK1	1.19	0.021

RNA was then isolated from the cell samples by TRI Reagent® method, quantified by O.D. measurement, and assessed for quality by chip-based capillary electrophoresis on an Agilent 2100 Bioanalyzer RNA 6000 Pico Chip. For each sample, a total of 1,000 nanograms of DNA-free total RNA was used as input into the Affymetrix miRNA FlashTag Biotin HSR RNA Labeling Kit to generate biotin-labeled RNA suitable for hybridization. Approximately 900 nanograms of the biotin-labeled sample was then loaded onto Affymetrix miRNA 4.0 microarrays according to manufacturer protocol. The microarrays were washed and scanned according to manufacturer protocol. Log 2 data for each microarray was exported from the Affymetrix Gene Expression Console and used for statistical analysis. Results are shown in TABLE 2.

TABLE 2

Selected miRNAs differentially regulated in lapatinib resistant H1975 lung cancers cells compared to the parental cell line.		
Altered Proteins	Fold Change Ratio	T-Test Analysis
miRNA-764	1.12	0.013
miRNA-3119	1.15	0.00522
miRNA-330-3p	0.43	0.0193

Without being limited to theory, it is possible that upregulation of CYP51A1 in drug resistant cells caused the cell to produce more cholesterol, which is needed for proper membrane and lipid raft formation. This could have caused enhanced EGFR downstream signaling, possibly outcompeting the effects of the inhibitor and leading to resistance.

The foregoing description of the specific aspects will so fully reveal the general nature of the invention that others can, by applying knowledge within the skill of the art, readily modify and/or adapt for various applications such specific aspects, without undue experimentation, without departing from the general concept of the present disclosure. Therefore, such adaptations and modifications are intended to be within the meaning and range of equivalents of the disclosed aspects, based on the teaching and guidance presented herein. It is to be understood that the phraseology or terminology herein is for the purpose of description and not of limitation, such that the terminology or phraseology of the present specification is to be interpreted by the skilled artisan in light of the teachings and guidance.

The breadth and scope of the present disclosure should not be limited by any of the above-described exemplary aspects, but should be defined only in accordance with the following claims and their equivalents.

All publications, patents, patent applications, and/or other documents cited in this application are incorporated by reference in their entirety for all purposes to the same extent as if each individual publication, patent, patent application, and/or other document were individually indicated to be incorporated by reference for all purposes.

For reasons of completeness, various aspects of the invention are set out in the following numbered clauses:

Clause 1. A method of treating cancer in a subject, the method comprising administering to the subject a tyrosine kinase inhibitor and an anti-resistance agent.

Clause 2. The method of clause 1, wherein the tyrosine kinase inhibitor and the anti-resistance agent are co-administered to the subject.

Clause 3. The method of clause 1, wherein the tyrosine kinase inhibitor is administered to the subject prior to the anti-resistance agent.

Clause 4. The method of clause 1, wherein the anti-resistance agent is administered to the subject prior to the tyrosine kinase inhibitor.

Clause 5. A method of treating cancer in a subject undergoing treatment with a tyrosine kinase inhibitor, the method comprising administering to the subject an anti-resistance agent.

Clause 6. The method of any one of clauses 1-5, wherein the cancer is a tyrosine kinase inhibitor-resistant cancer.

Clause 7. A method for preventing drug resistance or enhancing the therapeutic efficacy of a tyrosine kinase inhibitor in a subject having cancer and undergoing treatment with the tyrosine kinase inhibitor, the method comprising administering to the subject a pharmaceutical composition comprising an anti-resistance agent in an amount effective to attenuate resistance to the tyrosine kinase inhibitor.

Clause 8. A method of sensitizing a tyrosine kinase inhibitor-resistant cancer in a subject to the tyrosine kinase inhibitor, the method comprising administering to the subject an anti-resistance agent.

Clause 9. The method of any one of clause 1-8, wherein the anti-resistance agent comprises a CYP51A1 inhibitor, or an agonist of SEQ ID NO: 4 (miRNA-764), or a combination thereof.

Clause 10. The method of clause 9, wherein the anti-resistance agent comprises a CYP51A1 inhibitor.

Clause 11. The method of clause 10, wherein the CYP51A1 inhibitor comprises ketoconazole.

Clause 12. The method of clause 9, wherein the anti-resistance agent comprises an agonist of SEQ ID NO: 4 (miRNA-764).

Clause 13. The method of clause 12, wherein the anti-resistance agent comprises a polynucleotide having a sequence of SEQ ID NO: 4 (miRNA-764).

Clause 14. The method of any one of clauses 1-13, wherein the cancer comprises non-small cell lung cancer (NSCLC).

Clause 15. The method of any one of clauses 1-14, wherein acquired drug resistance to the tyrosine kinase inhibitor is decreased or prevented.

Clause 16. The method of clause 15, wherein tyrosine kinase inhibitor resistance is decreased at least 2-fold.

Clause 17. The method of clause 15, wherein tyrosine kinase inhibitor resistance is decreased at least 5-fold.

Clause 18. The method of clause 15, wherein the activity of the tyrosine kinase inhibitor is increased at least 2-fold.

Clause 19. The method of clause 15, wherein the activity of the tyrosine kinase inhibitor is increased at least 5-fold.

Clause 20. The method of any one of clauses 1-19, wherein tyrosine kinase inhibitor comprises lapatinib.

SEQUENCES

SEQ ID NO: 1

CYP51A1 polypeptide (509 amino acids, Accession No. KJ896685)
 MAAAAGMLLLGLLQAGGSVLQAMEKVTGNNLLSMLLIACFTLSLVYLIRLAAGHLVQLPAGV
 KSPPIYFSPFIFLGHAIAGKSPFLENAYEKYGPVFSFTMVGKTFYLLGSDAAALLFNSKN
 EDLNAEDVYSRLTPVFGKGVAYDVPNPVLEQKMLKSGNLIAHFQKHVSIIIEKETKEYFESW
 GESGEKNVFEALSELIIILTASHCLHGKEIRSQLNEKVAQLYADLDGGFSHAALLPGWLPSPF
 RRRDRAHREIKIDIFYKAIQKRRQSQEKIDDLQTLDDATYKDGRLTDDDEVAGMLIGLLLAGQH
 TSSTTSAWMGFFLARDKTLQKKCYLEQKTVCGENLPPLTYDQLKDLNLLDRCIKETLRLRPPVM
 IMMRMARTPQTAVGYTIPPGHQVCVSPVTNQRKDSWVERLDNPNDRYLQDNPASGKFAFVVPF
 GAGRHRICIGENFAYVQIKTIWSTMLRLYEFDLIDGYFPTVNYTTMIHTPENPVIRYKRRSK

SEQ ID NO: 2

CYP51A1 gene (22378 bp)

```

1  gtgacgcacg ggggtggcgcg cgtgggaccc gaggggtggg gctgggttta gtaggagacc
61  tggggcgaag cccctctgtg acgaccatct gccagcttct ctcgttccgt cgattgggag
121 gagcgggtgc gacctcgccc ttcaagtgtt cgcacggagt gaatggcgcg ggcggctggg
181 atgctctgtc tgggcttget gcaggcgggt gggctcggtc tggggcaggc gatggagaag
241 gtgacaggcg gcaacctctt gtccatgctg ctgatcgctt cgccttcac cctcagcctg
301 gtctacctga tccgtctggc gcggcgccac ctggctccag tgcccgcagg ggtggtaagt
361 acattcttta gggctctgag ggggcgcgcg ccgcagctga ggcggccgaa gggctggcgt
421 gggcggtccc gtggcccccga ccggctcagt ggatggcaag ggcggggcg actcgggcca
481 tgcttgccgt ggctttggtg gcaggcgcgc tgggggctgg agtagtggtt cggcgccggg
541 cactgctgct ggtggcgctg gctgtagcac ccgccattgc cttgtgtgg gggcggtgc
601 tggcctcccc ggctgtgtat ctgacccatg acggggtcgt ggttgcggca ttgtggttg

```

SEQUENCES

661	tagcggctctg	tactgaccgc	agcagtggtg	cccctagtg	cggtggctgg	attggcggct
721	gtgggttga	acgacccgg	ggtcgttggg	gcccttggtg	ggggctctga	cggagatgct
781	gttggcagct	ggcccgtcat	cctggaggct	gccctgtgtg	gttcagtggt	ctgtgggctg
841	tagcagtgcc	cctaattggtg	gtttataccc	atattaagga	ggaatgtgtag	agtgtggtaa
901	tggtagtgc	tgagtggtg	taagggcctt	cctctgatgc	taataatgta	acagtttctc
961	ggcggggagc	agtggctcac	gcctgtaatc	ccagcacttc	gggaggccga	agcgggcgga
1021	tcacctgagg	tcaggagtcc	cagaccagcc	tgaacaacat	ggagaaaccc	catctctact
1081	aaaatacaac	aaaacaaaac	aaaaattagc	tggatgtgg	ggcacacgcc	tgtagtccca
1141	gctgcttggg	aagctgaggg	cggagaatca	cttgaacctc	ggaggcggag	gttgagtaa
1201	accgagattg	cgccactgga	ctccagtcgt	ggcgacagaa	tgagactccg	tctcaaaaaa
1261	aaaaaaaatc	attttcttca	atttaacagc	cttattaacc	tagctttcaa	tctcccaaat
1321	gttatttgat	tgtgcctttt	acagtcagca	ataagtagct	tttgaaaact	acccttttac
1381	tgacaatgca	atgtacaaac	ttttgaccaa	gtagctttta	aaataatttt	tgtttgaaac
1441	ataccaggca	taagaagag	ttatttattt	atttattttt	ttctacaca	tgggactctt
1501	aaggaaatga	tatttgtctc	tgggaagaca	aagttaactt	tagtggttaa	agatagttct
1561	attagctgag	gtgtactgtg	agggtgtgg	gctcctttct	atttgagacc	accagagaat
1621	tgaggagtat	tacccttttt	cattattttg	tttgattttc	aggatactta	atgtgttaat
1681	ctgcaggtct	cattttgttg	catctaaaga	aacttttatg	aagaatgcta	gagttcttgc
1741	tagagctgat	ctactctctt	aaaaactcta	aatcagtggt	ctctagtcca	cttgagtgga
1801	gagaagcatg	agattgattg	tttactgaga	agtaaatata	gcttcttaaa	catttcctct
1861	ctttctatgc	tacaagtta	tgcttgcctt	tttctatacc	tcttttaagc	aagtatctgg
1921	gactaaaaat	gtgagtagta	gtagtagtaa	gtagtgaaga	aacaatatag	tggggcctct
1981	ggggacacga	attccacatt	tgggaattca	gccaaagtga	gatctaaaa	accacgggga
2041	aaaaaaccca	atacaaaata	acacaacaat	aaaaataaat	acaaataaaa	aaacacagtt
2101	taataacagt	ttatatagcc	ttacattgt	attgggtatt	gtaagtaata	tagaaatggg
2161	ttaaggtata	tgagagtag	tgcataggtt	atacgcaaat	actttgcat	ttatataaag
2221	ggacttgagg	atccctggat	acaaatctgt	gagggggtcc	tgggaccagt	tctccacaaa
2281	tgccaaggga	caagtgtagt	ttgacctttt	tggttttttg	ctactaatgg	ttagaaaagt
2341	tgccctggga	caccaataat	aattggacat	attctggaca	gtgtccatca	tttaatttta
2401	cagtgcctta	gtgtttatct	ggtcgtttat	cttataccgt	gttttgagtt	tctgttcttt
2461	tctacaatgt	ctactctctt	gaggtatttg	caatttggtg	gttctcaagt	tactcttgat
2521	gcttcccttt	gttttggtaa	cttttttttg	aagtcctaat	agctattttg	tttaattgtt
2581	tggtcatgaa	acgaaaactg	gtttctctct	tgaatgaaa	cacgaattga	atttactatt
2641	tttttctctt	gtagaaaagt	cctccataca	ttttctcccc	aattccattc	cttgggcatg
2701	ccatagcgt	tgggaaaaat	ccaattgaat	ttctagaaaa	tgcatatgag	aaggtaagtc
2761	ttccaaataa	ttagaggaaa	aaaaaaaaaa	caactagaga	agtgcctttt	aaactttttt
2821	aaaaaagtgg	cagaacattt	aaaaacattg	taatcatata	catatcctca	gtataggaaa
2881	caaaatggaa	actgctctgg	tttaagagat	ggtgtcttat	agatacctat	ccttttagct
2941	tttcccatgt	cctgggggtg	tctttgagac	accattgagg	aaacctgtag	tcttggaac
3001	tatgggttaa	aagccactgt	tctgagtttt	ctattcactt	attgtcatta	aaattgatat
3061	taattaaacc	tcattttttt	ttaccatgca	ctgtgggggt	ttctaaacct	gctctataca
3121	tcttctgtga	tttactgtgc	cacttgaatg	accacacatg	caccatagct	actcaattat
3181	ttgcccgtct	tctctcta	gagcttccct	gtgccaagtta	agccatttac	ttcacagtct
3241	cgctttggag	ttgtcactct	taactgtttc	acttccacaa	tattaaattta	gatatacctt
3301	tcgtagacca	taaccgtctc	tggtttgctt	gtgcaactcc	ttaaattata	actattcttt
3361	gacctcattg	gactctgcat	tccatttact	ttctcctgat	ccatcagcct	tcatcttcca
3421	cttctctctt	tcgcgttttg	gtccatggca	gtcgtttctt	gttacctctt	tggcaatact
3481	gtactttaaa	tttctctgac	cccgcactct	ttcattgtgt	tcagctggca	gaagtcaccc
3541	ttggaggcag	ccagtatttg	tctcctctgt	caccagatta	gtttcttctt	gattttatga
3601	ttgcctacct	taatgatatt	tgaacactgc	tccacagtcc	tattatgttc	ttgtgattgg
3661	gctacttttt	ccactcatta	cagtgactaa	ttcaaacctt	cacttttcta	aaactctgaa
3721	tctttctacc	tctccatcaa	agcagatgat	tttttctcct	gtttaggaga	caatgattaa
3781	aaacgttgat	ttaggagaca	attattaaaa	cattcaaaaga	aaacttctct	attttctcaa
3841	tttcaaatat	gcaaacctac	ttgtatttat	atagtaatcc	tattctcttt	cttctcatca
3901	cagttaataat	tatcaaacac	ttactttatg	ccagtactta	gtgctttaca	aagatcatct
3961	cactgaaagt	ccacaaaac	cctttcaggt	atatttggtt	tatagatgac	aaaactgaga
4021	agcagagagg	atatataatt	tcttcttggg	ctcactgcta	gacagtggtc	aagccaggat
4081	ttacacatgg	tctgatttct	gagcctatac	ttttattaat	gataacaata	atggaaaaac
4141	agtcattaa	atgctaagt	agccaaggta	ctcttctctg	cctgtatat	aaaatttggc
4201	agcagctctg	tgaagaactg	ctattattat	tattaccatt	ttatagggtg	gagaaacgaa
4261	acacagagag	actaagttct	ctgactatag	gaccaaaagt	atcacagcaag	taggtggagg
4321	agctgggatt	tgaacacgga	cagctctggc	cactgcgttc	taccactttg	attttattac
4381	aaactatatt	tgcctcttat	cggaggctga	actctccatc	cctcttttgt	ctcaggaact
4441	ttttactttt	atttgttttc	tcagtgtatt	gttgacttct	ttttcaatgg	catctttcct
4501	ttttctctga	aaaattcttg	tcaccctgtt	aaaaacttcc	tcaaaatggc	ttatgaggct
4561	ctgtatgggc	tagcactgct	taatgctcaa	ctctcatctc	ctcctttctc	tttctcttac
4621	ttttaggggc	tttgtgtatg	tttagctacc	aaaccagctc	ctcattcttc	tggctctaac
4681	ctagtgtgct	tttctctcat	taggtctccc	tttttttagt	tctctcatca	cagagttgct
4741	tttcttctgt	taatacttgt	cacatttgca	gttttatgtt	tgtaaagtgt	attatttgat
4801	taatttggat	tttttccaat	agactaagct	tggtgagttg	ggacagtatt	tttttcatg
4861	attatacccc	cagagctctag	tcttcaatca	taaccagaaa	actgcaaggg	aaagtattta
4921	acatctaacc	aaattaaat	aaaataaaaa	atgaagtcat	ttagttagg	tgaatagtgt
4981	ctaaaaataga	taataaaact	tgtagtgtct	tcacatagca	ggtaactatg	aaaagggtcaa
5041	attctttggc	tagtcttgtta	aaatttgttt	ttaaccaaag	ggggaagaag	tctatatttt
5101	cagaggtggt	catcacagaa	ttagctgtaa	taactaaaga	aaacctgac	atatcaccaca
5161	tatgtccaat	aatgaaagag	tagtcagtaa	attaacattg	tgtgttttat	atagacaata
5221	gaaacattg	tcaatataaa	ctgaaaaaag	cataataaac	agttatattt	atactacatt

SEQUENCES

5281	tgcaactaaa	tgaacataat	tataaatttg	gacaaaggaa	ggaggagtat	ggcaagatga
5341	aaagaattgc	tttaagggtt	atataatggtt	ttatTTTTTT	aataatgcat	tattttgtga
5401	ttttaaaaag	ttactgtcgt	agtgttgcat	atTTTTtgta	acatcactat	atgtactttt
5461	ctcttttttag	tatggacctg	tatttagttt	taccatggta	ggcaagacat	ttacttacct
5521	tctggggagt	gatgctgctg	cactgctttt	taatagttaa	aatgaagacc	tgaatgcaga
5581	agatgtctac	agtcgcctga	caacacctgt	gtttgggaag	ggagttgcat	acgatgtgcc
5641	taatccagta	ggtgacactg	ttaccataaa	taaagacaaa	tctataacct	agtagttata
5701	gctaataagt	agacattata	catttaaaat	gtagaaacag	ccaggcatgg	tggtctattc
5761	ctgtaatccc	agcacttttg	gaggccaagg	tggttggtatc	actcaaatgc	aggagtccaa
5821	gaccagcctg	gccaacatgg	tgaaacctcg	tctctactaa	aaatacaaaa	attagctggg
5881	tggggctggg	ggtgcacacc	tgtaaatcc	agctacttgg	gaggctgagg	catgagaatc
5941	gcttgaaacc	aggaggcgga	ggttgcagtg	agccgagatc	acaacactgc	actttagcct
6001	tggcaacaga	gtgagacct	gtctcaaaaa	cagaacaaaa	aaaccaaaaa	cacacacaca
6061	cacgcacgcg	cacacacaca	cacacacaca	cacacacaga	aaccaaccaa	acaaaaatgt
6121	aataaaaatgt	agaaccagtt	tattccttgg	ttcaaaaagtc	tgaagaatca	tgagaagaaa
6181	ggccatggat	aactgataag	taatgggtat	ttagttttat	atttgctgtc	atggctaaac
6241	aataattaaag	ggcttctgt	acaaaataatg	gaatcaatga	taacttagca	tactgggatt
6301	taatttgaag	gggttattag	acaatgctgt	tacttcatca	aaaggacttc	ctgcctaccc
6361	attcctgcct	gaaattctaa	cataagcgct	gttttagagat	tgctgacttc	agaagtccct
6421	ttttaatgca	acaacttcac	gtgtggggta	catctatgtg	tatgttttac	cctcaaaagc
6481	caaatacgaa	attgttttaa	gttgatatag	aacacaaatc	agacaatttg	ccccaatgct
6541	tggtatgggc	tctggctgtg	aatgtaacac	acattagcca	gtaccctagt	atagcagtta
6601	agagttaaca	ttaaatcttg	ttctagtga	tggggaatga	gggaatgaat	gcctctcctt
6661	aaggccaaaa	aacaggggcc	tgaaaaatcc	ctctgttcag	atataatata	tcatctagac
6721	tctattcatt	tagagtcaga	tagatctatt	catttagact	cttaaaatgt	aaatgcccaa
6781	agggttaaaa	ccattacttg	tgtagtggtt	acataattat	aataacctaa	atggatttta
6841	tgataaaaa	aaaatgtgtt	ttaatgccgt	atccccgttt	tgaatttttt	tgaagggttt
6901	cttggagcag	aagaaaaatgt	taaaaagtgg	ccttaacata	gcccacttta	aacagcatgt
6961	ttctataaatt	gaaaaagaaa	caaaggaaata	ctttgagagt	tggggagaaa	gtggagaaaa
7021	aagtaagcaa	aattgttttat	gtttgtccta	acattttctc	ttctctgtga	atagaaaaat
7081	agagtatata	tgtgtgtagt	atataaaaa	caaattacag	tgtatgtaaa	actaccttag
7141	atttatggga	gggttatgta	atgattacca	tgaagtgtga	actgagaatc	cagtttttat
7201	actgggctgc	aagttaagta	ttgccttcag	aagcaattgc	tgtgcccata	gtaggaagca
7261	acatctgccc	acagggcagc	aggacccagg	gcagcaggtc	actatattct	gggtctggcc
7321	tttggcctct	gtaagagttc	cagaatcttt	gtttttggta	tacttaagtt	gatattgata
7381	tattttctaa	ccatacaaga	aactgatgta	taaatagaaa	tgccaatgta	ataatgcatg
7441	tgagacatat	aattacagca	ccaagaaatc	cagaatattt	actgatattc	tttttatgta
7501	caaatataat	tggaagcca	gatgatcatt	ggaagtctat	ttagtgaatg	tggaattaac
7561	aggaaattaa	ttggaataat	tttattagtt	gtcatcaaat	tatgcttgcc	tggtgcattt
7621	gtctccagtg	ttgggatata	ctaattgggtg	attatagttt	tcttttacat	atcgccagta
7681	attccatttt	ggcccttgat	ttcctacttt	taacctggga	aataatctga	tctttggcta
7741	ctattccttg	ggaagtacct	tattattgtc	atatgcacta	taaaataacct	ttttctgct
7801	tttgttattg	tgacctggaa	atcaaataac	cacatttatt	ctttctatga	tgaagtgtct
7861	atgagtgggg	ttttgagatg	tgtttctggg	atctgttttg	gctgtttaga	gggacagggt
7921	gcttcacatt	gtttggttta	ttgccccctt	ttgttgttgt	acatagtcac	atgtctgtct
7981	acagactttt	tttgatgata	tgaataggat	ctgtttctct	cttgagttct	gttttttaatt
8041	ctcaattttc	tttcaatttt	tggaataagt	aatgagaata	atcttttttt	tctccctaga
8101	tgtgtttgaa	gctctttctg	agctcataat	tttaacagct	agccattgtt	tgcattggaaa
8161	ggaaatcaga	agtcacacta	atgaaaagg	agcacagctg	tatgcagatt	tggtatggag
8221	tttcagccct	gcagccctgc	tcttaccagg	ttggctgcct	ttgcctagtt	tcaggtatgg
8281	ataaagaata	tattacacta	ggttatttaa	ctttgtataa	ttattgtagt	gttggtatgc
8341	tttgccctaa	caagataaaa	aattaaacaa	gtaaaacata	caaaatgggt	aagattatga
8401	atcccccttc	ttctataaga	attcaagaca	aattttcttt	atataatgag	ctcatttaaa
8461	gtaagtttca	gtttattaaa	aagggtgattt	gttgtctgtc	tagtctaata	ttttatttat
8521	gtttttgttt	ttgagatgga	gtcttgcctt	gttgccccag	ctgtagtga	gtgggtgcat
8581	ctcggtccac	tgcagtcctt	gcctcctgtg	ttcaagcaat	tctcctgcct	catcctcctg
8641	agagctggga	ctacaggcac	gtgccaccat	gcccactaa	ttttctctat	tttagtagag
8701	acagggtttc	atcatgttgg	ccaggctggg	ttcaaacctc	tgacctcagg	tgatccacct
8761	gcctcagcct	cccaaatgtt	taggattaca	ggcgtgagcc	actgagccca	gcctagttta
8821	aaagcctgct	tacctcacgt	attccttatc	ctcaggaaag	tctctgaact	atacctaaaa
8881	gtgatcacgc	tcttctctag	cacttggttg	aaatctttgg	tggtctttta	ttgtattgtg
8941	aagtctttctt	gttttaataa	tttgtgcctt	tatttaattt	tctgtttctt	aaggacaggg
9001	actgcctctg	atataaagaa	atattgctct	taggacttga	tctatagctt	agtgtctagt
9061	gttttgcata	ttagtaggct	ttctgtactt	ttgttgattt	attggtgttt	agggtacaga
9121	tggggaggag	atagattgct	agtcctcttt	cttctatttc	tgccccctct	atctagttac
9181	agatttgaag	aggggtggga	gtaaaaggaa	gagccaggag	agattcccta	aagtctctgt
9241	gaactcatca	taccttatat	ttgcaaggag	ctttgcagtt	tcaaaatggt	ttcatatata
9301	ttatattaga	acaccagca	cagccctgga	ctcatagtgg	gttctccata	aatgtgcatt
9361	ctcttttttt	tttttttttt	ttggtgatgg	agtcctgtct	tctcgccag	gctggagtgc
9421	agtggcatga	gctcggtcca	ctgcaagctc	tgtctccag	gttcacgcca	ttctcctgcc
9481	tcagcctccc	gagttagctg	gactacaggc	accgcgccac	aagcctggct	aattgttttg
9541	tacttttagt	agagatgggg	tttccctgtg	ttagccagga	tggtcttgat	ctcccgacct
9601	tgtgatecgc	ccgcctcgcc	ctcccatagt	gctgggatta	caggcgtgag	ccactgcacc
9661	tgccccataa	atgtacattt	ctacctgcct	gtttctacct	gctctgtctc	ttggatgaag
9721	tcagagcttg	ctatgttagg	cccttcacat	tctggcccag	tctttctttc	ttctactcat
9781	accaactaat	ttaaccagat	tattcaattc	actttcttaa	acaggcctat	gttttctggg
9841	ttcgactgta	ttcatacagt	taagcccaaa	catcttctct	tctgtacaca	tggtttcagt

SEQUENCES

9901	tgatcctcaa	taacagatta	acagtcttgt	aaatgaaca	gagtaggagt	tttttttaga
9961	aggcttgatt	taagaggggg	cttgggagtc	agactgccta	gttttaaatt	ccagctccaa
10021	tgtttgcctt	ctgtgtgac	ttatgcagct	agctataact	tgagggtaat	agtatgtacc
10081	tcacaggaag	ataaaagtga	gtaattcatg	taaaacactt	aacatgggtac	ctgctacata
10141	gtgaacatac	tatttaaagg	taaagttag	gagtggaagc	ttgttttctg	aatctgctag
10201	tattttcacc	ccctacaaaa	aactattgta	ttagaaagtg	aaaagtagaa	ccagattcca
10261	tggaagaacc	agagtgaact	ttctgcttta	agacttgatt	tggtattaaa	attggaattt
10321	tatgttaatt	taaaagagta	tcctactttc	tggtgaactg	gaaaataact	ctaaaggaat
10381	ttcttgcttg	tttttaggct	ttagtgtgaa	cacaggcaat	gtgttaagaa	tctgggatat
10441	atatgtttaa	taaagcacag	ttcttgccct	tagggactat	ggacattttt	aacaatgtaa
10501	gattttcttg	acttcagta	tggtcctggg	ctgatttttt	ttgtcaatta	tttttagagtc
10561	attaaagttg	gttaaaataag	atgctttatg	ctcgggtcctg	gttctcaaaa	tgaattttgat
10621	cctagaaggt	tattttcttta	tttaagaaaa	tcactcttat	cttttaatta	cagacgcagg
10681	gacagagctc	atcgggaaat	caaggatatt	ttctataagg	caatccagaa	acgcagacag
10741	tctcaagaaa	aaattgatga	cattctccaa	actttactag	atgctacata	caagtaagag
10801	ctatttcagat	aacatattaa	gctgaagcag	gaaattacac	attaaaacac	agttaaatag
10861	tatttccagt	taaaaaacag	tgatgctggc	aaaataagtt	ggtagctgtg	atctttggac
10921	tctttaaatt	ggtgagacat	aaactattgg	catcctgtgt	cttactgtaa	tccagtgac
10981	tggtgatggg	aaaagtgttg	taataagctg	taattggagtc	ttttgtaatc	aaaatcggtt
11041	tggtctgggc	tgctctcttc	ctaagagaaa	aaaaactctt	gacttgtgat	agtcaaatat
11101	aagagaccac	tatacctgaa	aaatgtattc	attatgacac	tttattttaa	ggttagggca
11161	tgaatgtat	ctgccaaaat	gttaaatttg	tgctttgggt	tcattcctta	gggtggggcg
11221	tccttttgact	gatgatgaag	tagcagggat	gcttattgga	ttactcttgg	cagggcagca
11281	tacatcctca	actactagtg	cttggtggg	cttctttttg	gccagagaca	aaacacttca
11341	aaaaaatgt	tattttagaac	agaaaacagt	ctgtggagag	aatctgcctc	ctttaaactta
11401	tgaccaggtt	tggtggattt	ttcagtttca	ttgctgcctt	atgactttga	ggatctgtgg
11461	ctaatttttt	aaagggacaa	tttgagattt	tctatatact	atagctttaa	tgatcagct
11521	tctctatttt	tagcaaattc	cctataaact	tacctaaaat	atcttaattg	tattgcttct
11581	tgccatttaag	ctttatcaga	tatgttttgg	gttgatgggt	tagagatcct	tggggatggt
11641	tcttttggtac	ttacttctct	tgcttcaaa	tggtgcttct	gtacatagag	gatattatgt
11701	gcatgttgtg	tgctctatga	agtgtagaag	cctctgaatt	acttagaatt	ctgtatgtcc
11761	agagtggcct	gggcatgagc	agagacttct	aaaagtagta	gtagtagtag	taatgaggac
11821	aagacattta	gacacattac	atgcaacttg	ctgggtggaa	aggaagagag	gacaactcac
11881	tgacacacct	gacattccat	cttggaagca	aaccttgggt	atgtcatctt	cctgttatct
11941	tttgtgttct	tggtcctata	ttaatatggc	acattacact	gattttcaga	tgttaatgtg
12001	attcctggga	taaaactctac	tttgtcatgg	tgcatagtct	tttctatatg	ttactacata
12061	taaaacttgc	ggtgttttgt	tgaggatttt	tgcatctata	ttcataaagg	atattgatct
12121	ctagtttcac	tgtagtgtct	ttgactgggt	ttgatatacag	gatcatactc	atctcataga
12181	atgtatttgg	aagtattctt	tttttctct	aatttttgga	agagttttgt	gatgatgggt
12241	gttaaatcct	ttttacatat	ttgcaaaaat	tcagcagtg	aatcatctag	atctgtgctt
12301	ttctttctga	gaagacttta	cttactaatt	caattttatt	gttacagggt	tattcagata
12361	ttccattttc	ttctattgtc	gtttcagtag	tttatatctc	cttaggaatt	tgctcatttc
12421	atctaggtta	cctaatttgt	tggcatacaa	ttgttcatag	tattctcata	atccttttta
12481	tttctgtatg	ctcagtagtg	atgtctcaac	actcattctt	gtttttagta	acttaaaata
12541	acagcttaac	tgatatattt	acatagcata	aatccatcca	tttaaaatgt	acacttttgt
12601	gttttttagca	tattaaagag	tgggaaaccca	tcatacataat	ttaattttag	aacattttaca
12661	tcactcccaa	aagagagctg	gtaccattta	gcagtcagtc	ttcattctcc	ctgactgctg
12721	cccttgccaa	ccattaatct	ccttttgctt	ctgtgagttt	gctattcttg	gatatttcat
12781	gtaaatggga	tcatacaatt	tgtagtcttt	tgtagtacc	ttgttctact	tagcatgtta
12841	tcagggttct	tcctagtgtt	agcatgtatc	agtacttcag	cttttgttat	taccaataat
12901	attccattat	atggatagac	cacattttgt	ttattttgtt	atcagttgat	ggacatttga
12961	gtgtgttcca	ccttttaaac	tattatgaat	aatgcccctc	taaacgtttg	tgtagtgatt
13021	ttatgtggag	atgtgttttc	aattttgggg	ggctatacct	aggagtagaa	ttgctggggt
13081	ataaggttaac	tttgaagaac	tgccagactg	ttttaaaaag	tggtgtgcac	actttcaaat
13141	ctcactaaac	agtatatgtt	ggctcctgact	tcacccccct	accaaaactg	ttacttgatt
13201	tttttattat	aatagggtgt	aagtgtatact	tttttttttt	tttttgagag	agagtcttgg
13261	tgtagtgccc	aggtctagtg	gcaatggcgc	gaccttggtt	tactgcaacc	tgggtctccc
13321	aggttcaagc	tattctcctt	cctcagcctc	ccaagtagct	gggtacacac	caccacgcct
13381	ggctaatttt	tgattttttg	gtagagacaa	gggtgtacca	tattggccag	gctgggtctg
13441	aactcctgac	ctcaagtcat	ctgcccgcct	tggtctccca	aagtgtggg	attacaggtg
13501	tgagccacca	tgcccagttg	gtattttgtt	ttgattttgc	atttccctgg	tgactagtga
13561	tggtgagtg	cttatgagtg	gttctttggc	tttgggtatac	ttctttggag	aaatgtctgc
13621	tcacatcctg	ttcccatatt	taaaatgagt	tgctttttta	ttattgagtt	gtaagagttc
13681	atctattttt	ttttaatgtg	cttttggtgt	cagagaaact	aatgcctaatt	caaagtgtat
13741	gaagatttat	ttctgtgtat	tcttcttagt	gttttgtagt	ttcatatctt	acatttaggt
13801	ctttgatcca	ttatgaatta	atttatgtat	atgatgtgag	gtcatcattc	ttttgcattg
13861	gtttatccag	ttgtcccaaa	ctgtttgttg	aaaagactat	tttttccacg	ttgaattgtc
13921	tttgtaaaaa	aatctattat	agccaggcgc	agtggcacgt	gctctgattc	tcagctactg
13981	agaagctgag	atgggaaggt	cgcttgagct	caggacttgg	gggtccagcct	gggcaacata
14041	gcgaaacctt	gtctctgaaa	aaataaatac	attttaaaaa	gctctctgac	cataaaattta
14101	aggtcttatt	cttggaactca	gttctattcc	attgatattg	ttagctctgat	gccattacgt
14161	agttttgtta	taagtttttg	attcgggagt	gtgagtcctc	tgactttgtc	ttttcaagg
14221	ctgtttatct	actcctagtc	ccttttagttt	ccatattgaat	tttgggggtca	gtgtgtcagt
14281	ttctgcaaag	aagctagctg	agattttttg	caatgattgc	attgtatcgc	catatttaatt
14341	tgggagcaca	atttttagtct	ttaaatctgt	gaacatgaga	tgctttttct	ttatttttagt
14401	cttttaattt	ctttcaacaa	tgtttttatag	tttttggtgc	acaagtgtta	aacttctctt
14461	gttaaatgta	ttcttaagta	ttttattatt	gttatttttt	tgatgttatt	ctttcttctg

SEQUENCES

```

14521 ccagttccaaa tctgctgttg atccccctcgg gtgaattttt catttcagtt ctcatacttc
14581 tcagttctttg aattttctatt tgggtctctta aaaaaataat atattgatat tctccatttt
14641 actagagata tctaggcata ttttgcataa gtcttttgaa cctgtttata atagctgatt
14701 taaattcatt atctagtaag tccaatgtct gggcttcttc atggatagtt tctattaaac
14761 tggctgtcttt ttctatgtac tggccatact ttctgttttt ggtgtgtttt ttgtaatttt
14821 tttgttgtaaa actgtacatt taaaataatg tggcaactgt ggaaatcaga tgccctcttc
14881 cctgggtttta ttgttgctgg ctctttgttg ttgttgttgt tgcgtgtgct gtttgtttac
14941 tgcgtttctct ggattaaata tgtcattcct tgttcagtga ggtcactgaa atctctgctt
15001 gcttacttta tggggcatct aatatttggg cagagattta ctgaagtgtc ttgaacagcc
15061 agtctcctag cttttgctga aaggctctgt atgtgtgtgt taggggatgt tattaacact
15121 ccaacaggca gttacaagtc tgccttcact acctgtgtgt acaggtcagc cagaggtaaa
15181 agattacagc cttctagatc ttacctgggc atatgcattg tcttatacat atgtgtggcc
15241 ttcaagattc tcttatgttg gaacttttca aagtctcctg tggacatctt actccccagt
15301 tttccctttt aaactctctt ttctgtctct tagcaccacg tgatctcacc atctcaggcg
15361 ccttcagttg taacaatttt ttgctaaata tttttggaaa atttgcctcg gctcctctaa
15421 tagttgttag gcttctggct ttcacagctg ctatagttgt catgctgttg gtttccgggg
15481 ctaccattgga ttgggggaga ggaggatgaa agaaatacaa cttacactac cacaaagcct
15541 actcttcttta ccaagattca gatttctttt tcttgaatta actctcctta gattgttgca
15601 agcctttggg taatcttcca gaattttgaa aaagtgtgaca ttaagattgt tgctactgtt
15661 ttcatttttt ggaggagtga atttttgtag gttcttactt cattcttcag ggcaatcgct
15721 tctgttaact tgccctcctt tttcaccatg gacagtggtg gagcatgata accccagcca
15781 ccttgaaacca gttacctctg tacttttagc tggaaatcaa gctgtcttgt actaaactag
15841 aagttaaaact aatttttttg actgttgaag tatgttattt ataacaatca ggaaatgctt
15901 tctcatttta gctcaaggat ctaaatttac ttgatcgtcg tataaaagaa acattaagac
15961 tttagacctcc tataatgatc atgatgagaa tggccagaa cctcagggtg agtatcttgg
16021 ctacattttt cctctctata cccctctata tctcaaaaag aagaaatagg tgggtgtggt
16081 ggttcacacc tgtaatctca acactttggg aggctgaggt gggaggatca cttgaggcca
16141 gaatttgaga ccagcctggg caacatagtg agactgacct catctctaca aaatttttct
16201 taaaaaattg ctggccataa tggcacatgc ctgtggtccc agctgcttgg gaggtgatg
16261 tgggtagatt gcttgagcct gggagggtga aactgcagta atccatgatc acgccactgc
16321 attgctgcct gggcaacaga gcaagacct gtctcaaaaa aaataaaaaa aaaaaagaaa
16381 gaaaaagaaa agagggaagt gagtagcata aaagagattt ttttaatta aaaaagtaga
16441 ataactcatt ctacctaatc ttcagtttta tatactctaa aaacatattt ttacctaat
16501 gtagatagta tacgtgctaa tctgtttttt ttttttttga gacggcattt cactcttgtt
16561 gccaggctg gagtgcagtg gtgcgatctc agctcactgc aaacctcgcc tcccgggttc
16621 aagcaattct tctgctcag cctcccaagt agctgggatt acaggggcat gccaccatgc
16681 ctggctaatc ttttgtattt tagtagagat ggggtttatc catgttggtc aggtgatctg
16741 cgaactcccg acctcagggt atccaccgcg cttggcctcc caaagtctcg ggatacaggg
16801 tgtaatcccg cgcctcctct acatgctaat ctttaagtct aatcatgttc tgcatttttc
16861 ttaacaattt ggggttttaa aaatcaaagt acatattttt cttggtttta aaaaataact
16921 tttgttgtta aaaatttgtt atatgaagtg taaaaattga tagtgaaagc ctctctgaaa
16981 ttccaaccct acctccaagg cattatgggt ttgatttgtg tactgtgtac ttccaacca
17041 acgtggctc actggaatc atcttgagtt aaaataattt ttagtttgct tattatctag
17101 ccagttttta aatatatgta cagatggttc ttgatttatg tgattcaact tataattttt
17161 tgacttttat atggatttat caggatgtaa acctatcata agtcaaggag catctgagta
17221 tcccatgtat attcatgctt tattacacaa tgatctgatt atttgcagc acatttttaa
17281 attctctaat gaaatgtgtg gcttttgttt atagactgtg gcagggtata ccatctctcc
17341 aggacatcag gtgtgtgttt ctcccactgt caatcaaaga cttaaagact catgggtaga
17401 acgcctggag tttaactcct atcgctactt acaggataac ccagcatcag gggaaaagtt
17461 tgcctatgtg ccatttggag ctggtaagat gattatattt tagattgtaa atgtttgttc
17521 tgataacata ttgtctctcg tcaaaaattt ccgaattgtg tttaaaaaat atctctccct
17581 ttctcatag ggacattttt gcaaaacttt ttaggagaag aatctttata agttggagaa
17641 aaatattttc ttgtaccata atggaattgt tccataaatc cttatataat gcttcaacta
17701 ttctaaacct gtctggtttt attaggtcta atttttatag aacatccttg ttttccctta
17761 caatggtatt taaagctctt tgtggattct cttttaaaga accattggag tcagcacacc
17821 attcagggaa taacagatta ctagcatttc acaaaaaagc aaaggcagtc ttttaaaatt
17881 aaagctcttc tgcagctgta gtcaacattt ttgctctctg aatatccgta tgagaaaatg
17941 gtcttttaaa ttgggcaggt tgtgtgtagg cttgcaaat tcatttccag taagatccta
18001 aaataattta gctataacct tgtttctcca gtaatttctc tgtccattgg ttctctgtac
18061 tgattaaact atattctatg ctttagtctt tccaaaggga tcatttaaat gacagatgac
18121 ttgtcatttg tcacactttt tccacatata aaggaaaaata taaagtcctt tgggaacttc
18181 agatcttaac tttatgtaat aaatttaata ctgtggtgta taacacaata tataaaagaa
18241 tcatagtttt ttttttgaga gagtcttgct ctgtcaccca gtctggagtg cagtggcaca
18301 atctctcagc tcaactgcaac ctccacctct gggttcaagt aattctcgtg ccttagcctc
18361 ctgagtagct gggattacag gtgtgtacca ccacgctcag ctaatttttg agcttttagt
18421 agagactggg ttttgcctag ttggccaggc tggctctgaa ttccaggctt gaagcaatct
18481 gccacacctg gccctccaca gtgctgggat tacaggcgtg agccatgcca cctggccaaa
18541 gaatcagatt gttaacagat gggaagagca ttagtcttgt agcccaaat ctgccccaaa
18601 gaggaatcgt ttctaacta gtaattatct ggtttccact tgaactttac tagaaatggg
18661 ttgtgggttg ttcagttacc ttttatgatg gctcattcta tgtttggaca gctgtcattt
18721 tttagacctt atgtttaaag tgaaatctgt ttctttttaa catctcattt atagttgttc
18781 ctaaccatag tctctgaact tatattgtat gaggtatttg agtacagata taatgtctcc
18841 tccatctttt tttcaactct tgtgttagtt tcttagggct tctgtaacta attacaatat
18901 ggggtgctta aaacaataga aatatattct atcacagttt tggaggctgg aaggtgaaa
18961 tcaaggtatt ggcaggaccg tgctcctcct taaggttcta caggagaatc cttccttgca
19021 tctcctagc ttctggtggc ctttggcaac ctttggcttg taactacatt gttccaatta
19081 ctaccctctg cttcaacagg ctttcttctt gttcatgtct ctgtatctta acatggcatt

```


SEQUENCES

```

19141 cttataagga caccagtcac tggatctaag tccctacccta agtcagggtc atctcatctt
19201 aaataattgt gtatataaag atccctatttc ccaattaaga tcacattcta aggttctgga
19261 tggacttgaa tttatggggg gatatatgat cttacgttaa tcttggttaa tatcacatta
19321 catgtctcta atttctttac tcattctttt acctcgtaac tgtgctgttt atttatgttg
19381 gtgcataatg ttcattcatt ttcataatat tacattttgt gaatcatcag aatttatcta
19441 ctcttatggt gatccaatta ggatactctt tgcttggtgc gattaaatcc ttggactatt
19501 cttcctgtaa gccaaagcttc ccttttagttg ttatatttga aatatggacc aatttgtaaa
19561 tgctcatctt aaatgtcac cctagaaata agtacagtta tgggccaagc aagcactgtg
19621 ctaagcacta tcagtttagg tttttctttt tgatgaaaaa tcttgcaatg aaatgcccac
19681 atcttaagtc aacattcatt gagttttgac aaatgaataa ccttttagtt agtccaatgt
19741 atcaatcttt taaatgggta ttgctttctg gccctgtctt aaaaattttt cttagccctt
19801 gagtcacgaa gatattctcc tgcttctctc tactgaaatt tatgctgtta gcatcatggt
19861 ttgtgacctt tcttgaatta gtatttgatt atgggtgtgac ataggagtgt aatttcattt
19921 ttcccccacg taatatctag ttattctctg accctatggt gaaaagactt gctttctctc
19981 attggcttgc ttgtgtgtct gtaactgataa tcaaaataacc ataaaaatat tctgttctgg
20041 gctctctgct ctgttccatt gatctatttg ttgatcctta cctagtacca ctctgtttta
20101 tctttagtct tgaagtcaga ttgaaatca gttttatgtc ctccaactca gttcttttct
20161 caagattgct ttggatctcc taggtccttt gcatttttat atgcatttta gaattcagctt
20221 gtcagtttct acatgggtgt gacttttttag tatattattt tgggttcat aaatctcatt
20281 ttcttccata catttataat gacatttgag gtttgattgg aaggttttca tattgacttt
20341 taactagggc tttcttggga caaacagaaat attctactat attcccaaac tagattacca
20401 tcttatgatt caaatcttcc atatatttaa cccagatata tattttcaga aaaagtaatt
20461 ggaaaaagtt tgatgcact caagtaactgt tttcctaaaa tgtggtattg aaaatctctc
20521 ggaattttta ataatctcat ttgttttatg tgaaaagaat gtcattcttt tattatatta
20581 tctgtacatt tgctgttcat ctaaaatgta gataatatca cccagggtca aaaaggatga
20641 gaaagaattt aaactgattc ttataacttt tctttttttt tagggcgctca tcgtgtgatt
20701 ggggaaaaatt ttgcctatgt tcaaaatga acaatttgggt ccactatgct tcgtttatat
20761 gaatttgatc tcattgatgg atactttccc actgtgaatt atacaactat gattcacacc
20821 cctgaaaacc cagttatccg ttacaaacga agatcaaaat gaaaaagggt gcaaggaaacg
20881 aatataatgt attatcactg taagccacaa aggcattcga agagaatgaa gtgtacaaaa
20941 caactcttgt agtttactgt ttttttaagt gtgtaattct aaaagccagt ttatgattta
21001 ggatttttgt aactgaatgg ttctatcaaa tataatagca ttgaaacat tttctaatag
21061 ttatgatcat tatacatgtg ctttcaggaa gttccttgggt gaaacaattg ttgagggggg
21121 attcaggtaa ttggcagatt ctaaaataa taatttccag atagtaattt taagagtact
21181 catcgctctt gccaaataag ttcagggtat tcaaatcttg gactagtctt gcaaggatata
21241 aagaataaaa atcccagtg gaactttgga aaccacagtt tattattatt tatctgggca
21301 attattgtgt gtgtgaggat ggaagggtag ggaataatcg aacatctaaa gccttgaata
21361 agagaatact aattgttttg gtatgatgat actcagaaat ggagatatta taggaaaaag
21421 aaatcctttg gaattttaac gcaatcactg gcataatggga aattaaagga tccaggacca
21481 tatttgataa gagttcctaa aaataatgta attattaatg ctaaagactg ctcatgtatc
21541 ttgatctaat tactaaataa ttacatattt atttacctga taaatagtta tctagtctca
21601 caaggtcaca ttatgtgga agtccaaagt caagtccctt ggggataatt ttgttttggc
21661 tcagttgttc cctgcttctt tttttttttt ttttttttga gatggagtct cgctctgttg
21721 cccaggctgg agtgcagtg tgcatctca gctcactgca tctctgctt cccgggttca
21781 agcaattctc tgccctcagc tcccaagtag ttgggattac aggcacctgc caccatgctt
21841 ggctaatttt ttgtattttt agtagagacg ggggtttcac tatgttggtt aggtggtctt
21901 tgaactctgt accctgtgat ccaccgcctt tggcctccca aagtgtctggg attacaggca
21961 tgagccaccc caccctggct tccctgcttc cctcttagaa tccaattagg gatgtttgtt
22021 actactcata ttgattaaaa cagttaacaa acttttttct ttttaaaatg tgagatcagt
22081 gaactctggt ttaagataa tctgaaacaa ggtccttggg agtaataaaa ttggtcacat
22141 tctgtaaagc acattctgtt taggaatcaa cttatctcaa attgtaactc ggggctaac
22201 tatatgagat ggcgtgaaaa ataccacatc gtctgttttc actaggatgat gccaaaatat
22261 ttgtctttat gtatattaca gttcttttta aaacactgga agactctagt taaactctaa
22321 ttgtgaaggc agaactctct ctaatttttc agattaaaaa tctctttgaa aaaatata

```

SEQ ID NO: 3

CYP51A1 mRNA (1659 nt, Accession No. KJ896685)

```

1 gttcgttgca acaaatgtat gagcaatgct tttttataat gccaaacttg tacaataaag
61 ttggcatggc ggcggcggct gggatgctgc tgctgggctt gctgcaggcg ggtgggtcgg
121 tgctggggcca ggcatggag aaggtgacag ggcgcaacct cttgtccatg ctgctgatcg
181 cctgcgcctt caccctcagc ctggtctacc tgatccgtct ggcgcgcggc caccctggtc
241 agctgcgcgc aggggtgaaa agtcctccat acattttctc cccaattcca ttccttggcg
301 atgccatagc atttgggaaa agtccaattg aatttctaga aaatgcataat gagaagtatg
361 gacctgtatt tagttttacc atggtaggca agacatttac ttacctctg gggagtgtatg
421 ctgctgcact gctttttaat agtaaaaaat aagacctgaa tgcagaagat gtctacagtc
481 gcctgacaac accctgtgtt gggaaggag ttgcatacga tgtgcctaac ccagttttct
541 tggagcagaa gaaaatgtta aaaagtggcc ttaacatagc ccactttaa cagcatgttt
601 ctataattga aaaagaaaca aaggaatact ttgagagtgt gggagaaaagt gggagaaaaa
661 atgtgtttga agctctttct gagctcataa ttttaacagc tagccattgt ttgcatggaa
721 aggaaatcag aagtcaactc aatgaaaagg tagcacagct gtatgcagat ttggatggag
781 gtttcagcca tgcagcctgg ctcttaccag gttggctgcc tttgcctagt ttcagacgca
841 gggacagagc tcactgggaa atcaaggata tttctataa ggcaatccag aaacgcagac
901 agtctcaaga aaaaaattgat gacattctcc aaactttact agatgctaca tacaaggatg
961 ggcgtccttt gactgatgat gaagtagcag ggatgcttat tggattactc ttggcagggc
1021 agcatatact ctcaactact agtgcttggg tgggcttctt tttggccaga gacaaaaacac
1081 ttcaaaaaaa atgtttattt gaacagaaaa cagtctgtgg agagaactcg cctcctttaa
1141 cttatgacca gctcaaggat ctaaatttac ttgatcgtg tataaaagaa acattaagac

```

-continued

SEQUENCES

```

1201 ttagacctcc tgtaatgac atgatgagaa tggccagaac tcctcagact gtggcagggt
1261 ataccattcc tccaggacat caggtgtgtg tttctccac tgtcaatcaa agacttaaag
1321 actcatgggt agaagcctg gactttaatc ctgacgcta cttacaggat aaccagcat
1381 caggggaaaa gtttgcctat gtgccatttg gagctgggcg tcatcgttgt attggggaaa
1441 attttgccta tgttcaaatt aagacaattt ggtccactat gtttcgttta tatgaatttg
1501 atctcattga tggatacttt cccactgtga attatacaac tatgattcac acccctgaaa
1561 acccagttat ccgttacaaa cgaagatcaa aatgcccaac tttctgtac aaagttggca
1621 ttataagaaa gcattgctta tcaatttgtt gcaacgaac

```

SEQ ID NO: 4

miRNA-764 MI0003944

aaucuaggaggcaggugcucacuuuguccucccaugcuuggaaaaugcaggaggaggccaau

guggcaacuguuaccaugauu

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 4

<210> SEQ ID NO 1

<211> LENGTH: 509

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 1

```

Met Ala Ala Ala Gly Met Leu Leu Leu Gly Leu Leu Gln Ala Gly
1      5      10      15
Gly Ser Val Leu Gly Gln Ala Met Glu Lys Val Thr Gly Gly Asn Leu
20     25     30
Leu Ser Met Leu Leu Ile Ala Cys Ala Phe Thr Leu Ser Leu Val Tyr
35     40     45
Leu Ile Arg Leu Ala Ala Gly His Leu Val Gln Leu Pro Ala Gly Val
50     55     60
Lys Ser Pro Pro Tyr Ile Phe Ser Pro Ile Pro Phe Leu Gly His Ala
65     70     75     80
Ile Ala Phe Gly Lys Ser Pro Ile Glu Phe Leu Glu Asn Ala Tyr Glu
85     90     95
Lys Tyr Gly Pro Val Phe Ser Phe Thr Met Val Gly Lys Thr Phe Thr
100    105    110
Tyr Leu Leu Gly Ser Asp Ala Ala Leu Leu Phe Asn Ser Lys Asn
115    120    125
Glu Asp Leu Asn Ala Glu Asp Val Tyr Ser Arg Leu Thr Thr Pro Val
130    135    140
Phe Gly Lys Gly Val Ala Tyr Asp Val Pro Asn Pro Val Phe Leu Glu
145    150    155    160
Gln Lys Lys Met Leu Lys Ser Gly Leu Asn Ile Ala His Phe Lys Gln
165    170    175
His Val Ser Ile Ile Glu Lys Glu Thr Lys Glu Tyr Phe Glu Ser Trp
180    185    190
Gly Glu Ser Gly Glu Lys Asn Val Phe Glu Ala Leu Ser Glu Leu Ile
195    200    205
Ile Leu Thr Ala Ser His Cys Leu His Gly Lys Glu Ile Arg Ser Gln
210    215    220
Leu Asn Glu Lys Val Ala Gln Leu Tyr Ala Asp Leu Asp Gly Gly Phe
225    230    235    240
Ser His Ala Ala Trp Leu Leu Pro Gly Trp Leu Pro Leu Pro Ser Phe
245    250    255

```

-continued

Arg Arg Arg Asp Arg Ala His Arg Glu Ile Lys Asp Ile Phe Tyr Lys
 260 265 270
 Ala Ile Gln Lys Arg Arg Gln Ser Gln Glu Lys Ile Asp Asp Ile Leu
 275 280 285
 Gln Thr Leu Leu Asp Ala Thr Tyr Lys Asp Gly Arg Pro Leu Thr Asp
 290 295 300
 Asp Glu Val Ala Gly Met Leu Ile Gly Leu Leu Leu Ala Gly Gln His
 305 310 315 320
 Thr Ser Ser Thr Thr Ser Ala Trp Met Gly Phe Phe Leu Ala Arg Asp
 325 330 335
 Lys Thr Leu Gln Lys Lys Cys Tyr Leu Glu Gln Lys Thr Val Cys Gly
 340 345 350
 Glu Asn Leu Pro Pro Leu Thr Tyr Asp Gln Leu Lys Asp Leu Asn Leu
 355 360 365
 Leu Asp Arg Cys Ile Lys Glu Thr Leu Arg Leu Arg Pro Pro Val Met
 370 375 380
 Ile Met Met Arg Met Ala Arg Thr Pro Gln Thr Val Ala Gly Tyr Thr
 385 390 395 400
 Ile Pro Pro Gly His Gln Val Cys Val Ser Pro Thr Val Asn Gln Arg
 405 410 415
 Leu Lys Asp Ser Trp Val Glu Arg Leu Asp Phe Asn Pro Asp Arg Tyr
 420 425 430
 Leu Gln Asp Asn Pro Ala Ser Gly Glu Lys Phe Ala Tyr Val Pro Phe
 435 440 445
 Gly Ala Gly Arg His Arg Cys Ile Gly Glu Asn Phe Ala Tyr Val Gln
 450 455 460
 Ile Lys Thr Ile Trp Ser Thr Met Leu Arg Leu Tyr Glu Phe Asp Leu
 465 470 475 480
 Ile Asp Gly Tyr Phe Pro Thr Val Asn Tyr Thr Thr Met Ile His Thr
 485 490 495
 Pro Glu Asn Pro Val Ile Arg Tyr Lys Arg Arg Ser Lys
 500 505

<210> SEQ ID NO 2

<211> LENGTH: 22378

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 2

```

gtgacgcacg ggggtggcgcg cgtgggaccc gaggggtggg gctgggttta gtaggagacc   60
tggggcaagg cccctgtgg acgaccatct gccagcttct ctcttccgt cgattgggag   120
gagcgggtggc gacctcgcc ttcagtgttt ccgacggagt gaatggcggc ggcggctggg   180
atgctgctgc tgggcttgct gcaggcgggt gggcgggtgc tgggccaggc gatggagaag   240
gtgacaggcg gcaacctctt gtccatgctg ctgatgcct gcgccttcac cctcagcctg   300
gtctacctga tccgtctggc cgccggccac ctggtccagc tgcccgcagg ggtggtacgt   360
acattcttta gggctctgagt ggggcgcgcg ccgcagctga ggcggccgaa gggctggcgt   420
gggcggctcc gtggccccga ccggctcagt ggatggcaag ggcgggggcg actgcggcca   480
tgcttgccgt ggctttggtg gcaggcgcgc tgggggctgg agtagtggt ggcggcggcg   540
cactgctgct ggtggcgtg gctgtagcac ccgccattgc cttgtgttg ggggcgggtg   600
tggcctcccc ggtgtgtat ctgacccatg acggggtcgt ggttgcgga tttgtggtg   660
tagcggctctg tactgaccgc agcagtgggtg ccctagtgg cggtggttg attggcggct   720

```

-continued

gtgggtttga acgacccggt ggtcgttggg gcccttgggt ggggtcctga cggagatgct	780
gttggcagct ggcccgctcat cctggaggct gccctgtgtg gttcagtgtt ctgtgggctg	840
tagcagtgcc cctaattggtg gtttataccc atattaagga ggatgtgtag agtgtggtaa	900
tggtagtgtac tggagtgtgg taagggcctt cctctgatgc taataatgta acagtttctc	960
ggccgggagc agtggctcac gctgtaatc ccagcacttc gggaggccga agcgggcgga	1020
tcacctgagg tcaggagtgc cagaccagcc tgaacaacat ggagaaaccc catctctact	1080
aaaatacaac aaaacaaaac aaaaattagc tggatgtggt ggcacacgcc tgtagtccca	1140
gctgcttggg aagctgaggc ccgagaatca cttgaaccta ggaggcggag gttgcagtaa	1200
accgagattg cgccactgga ctccagtctg ggcgacagaa tgagactccg tctcaaaaaa	1260
aaaaaaaaatc attttcttca atttaacagc cttattaacc tagctttcaa tctccaaat	1320
gttatttgat tgtgcctttt acagtcagca ataagtagct tttgaaaact acccttttac	1380
tgacaatgca atgtacaaac ttttgaccaa gtagctttta aaataatttt tgtttgaacc	1440
ataccaggca taagaaagag ttattttattt atttattttt ttctacaca tgggatcttt	1500
aaggaaatga tatttgtctc tgggaagaca aagttacttt tagtgtttaa agatagtctc	1560
attagctgag gtgtactgtg aggttgtggt gctcctttct atttgagacc accagagaat	1620
tgaggagtat tacccttttt cattattttg tttgatttcc aggatactta atgttgtaat	1680
ctgcaggctc cattttgttg catctaaaga aacttttatg aagaatgcta gagttcttgc	1740
tagagctgat ctactctctt aaaaactcta aaatcagtg gctctagtca cttgcagtga	1800
gagaagcatg agattgattg tttactgaga agtaaatata gcttcttaaa catttccctt	1860
ctttctatac tacaagttac tgcttgtctt tttctatacc ttctttaagc aagtatctgg	1920
gactaaaatt gtgagtagta gtagtagtaa gtagtgaaga aacaatatag tgggcccctc	1980
ggggacacga attccacatt tgggaattca gccaaagtga gatctaaaa acccagggga	2040
aaaaaaccca atacaaaata acacaacaat aaaaaataat acaataaaa aaacacagtt	2100
taataacagt ttatatagcc ttacattgt attgggtatt gtaagtaata tagaaatggt	2160
ttaagggtata tgagaggatg tgcataggtt atacgcaaat actttgccat tttatataag	2220
ggacttgagg atccctggat acaaatctgt gaggggggtc tgggaccagt tctccacaaa	2280
tgccaaggga caagtgtagt ttgacctttt tgggtttttg ctactaatgg ttagaaaagt	2340
tgcttgagga caccaataat aattggacat attctggaca gtgtccatca tttaaattta	2400
cagtgcctta gtgtttatct ggtcgtttat cttataccgt gttttgagtt tctgttcttt	2460
tctacaatag ctactctctt gaggtatttg caatttggtt gttctcaagt tacttctgat	2520
gcttcccttt tttttggtta cttttttttg aagtcttaat agctattttg ttttaattgtt	2580
tggatcatgaa acgaaactgg gtttctctct tgaaatgaaa cacgaattga atttactatt	2640
tttttctctt gtgaaaaagt cctccataca ttttctcccc aattccattc cttgggcatg	2700
ccatagcatt tgggaaaagt ccaattgaat ttctagaaaa tgcatatgag aaggtaagtc	2760
ttccaaataa ttagaggaaa aaaaaaaaaa caactagaga agtgcttttt aaactttttt	2820
aaaaaagtgg cagaacattt aaaaacattg taatcatata catatcctca gtataggaaa	2880
caaaatggaa actgctctgg tttaagagat ggtgtcttat agatacctat ccttttagct	2940
tttcccatgt cctggggtcg tctttgagac accattgagg aaacctgtag ttctggcaac	3000
tatgggttaa aagccactgt tctgagtttt ctattcactt attgtcatta aaattgatat	3060

-continued

taattaaccc	tcatttttct	ttaccatgca	tctgtggggg	tttctaacct	gctctataca	3120
tcttctgtga	tttactgttc	cacttgaatg	accacatga	caccatagct	actcaattat	3180
ttgccgctct	tctctcta	gagcttccct	gtgccagtta	agccatttac	ttcacagtct	3240
cgttttgac	ttgtcactct	taactgtttc	acttccacaa	tattaattta	gatatcctat	3300
tcgtagacca	taccgtctcc	tggtttgctt	gtgcaactcc	ttaaattata	actattcttt	3360
gacctcattg	gatcttgc	tccatttact	ttctcctgat	ccatcagcct	tcattcttca	3420
ctttcctctt	tccgctttgg	gtccatggca	tgctgtttct	gttacactct	tggcaatact	3480
gtactttaaa	tttctcgac	cccgcattct	ttcattgtgt	tcagctggca	gaagtcaccc	3540
ttggaggcag	ccagttattg	tctcctcttg	caccagatta	gtttcttctt	gattttatga	3600
ttgcctacct	taatgatatt	tgaacactgc	tccacagtcc	tattatgttc	ttgtgattgg	3660
gcctactttt	ccactcatta	cagtgcactaa	ttcaaacctt	cacttttcta	aacttctgaa	3720
tctttctacc	tctccatcaa	agcagatgat	tttttctcct	gtttaggaga	caatgattaa	3780
aaacgttgat	ttaggagaca	attattaaaa	cattcaaaga	aaacttcctc	attttctcaa	3840
tttcaaatat	gcaaacctac	ttgtatttat	atagtaatcc	tattctcttt	cttccctatca	3900
cagtaataat	tatcaaacac	ttactttatg	ccagtactta	gtgctttaca	aagatcatct	3960
cactgaagct	ccacaaaaac	cctttcaggt	atatttggtt	tatagatgac	aaaactgaga	4020
agcagagagg	atatataatt	tcttcttgga	ctcactgcta	gacagtggcc	aagccaggat	4080
ttacacatgg	tctgatttct	gagcctatac	ttttattaat	gataacaata	atggaaaaca	4140
agtcattaag	atgctaagta	agccaaggta	ctcttctctg	ccctgtatat	aaaatttggc	4200
agcagctctg	tgaagaactg	ctattattat	tattaccatt	ttatagggtga	gagaaacgaa	4260
acacagagag	actaagtctt	ctgactatag	gaccaaagtc	atacagcaag	taggtggagg	4320
agctgggatt	tgaacacgga	cagtctggct	cactgcgttc	taccactttg	attttattac	4380
aactatattt	tgctctttat	cggaggctga	actctccatc	cctcttttgt	ctcaggaact	4440
ttttactttt	atttgtttct	tcagtgtatt	gttgacttct	ttttcaatgg	catctttcct	4500
ttttctctga	aaaattcttg	tcaccggtt	aaaaacttcc	tcaaatggc	ttatgaggct	4560
ctgtatggtc	tagcactgcc	taatgtctaa	ctctcatctc	ctcctttctc	tttctcttac	4620
ttttagggcc	tttgtgtatg	tttagctacc	aaaccagctc	ctcattcttc	tggctctaac	4680
ctagttgtct	tttctctat	taggtctccc	tttttttagat	tctctcatca	cagagttgct	4740
ttcctttctg	taatacttgt	cacatttgca	gttttatgtt	tgtaaatgtg	attatttgat	4800
taatttgtat	tttttccaat	agactaagct	tggtgagttg	ggacagtatt	ttttttcatg	4860
attatacccc	cagagtctag	tcttcaatca	taaccagaaa	actgcaaggg	aaagtattta	4920
acatctaacc	aaattaatat	aaaataaaaa	atgaagtcat	ttagtgtagg	tgagatagtg	4980
ctaaaataga	taaataaact	tgtagtgtct	tcacatagca	ggtactatag	aaaagggtcaa	5040
attctttggc	tagtcttgta	aaatttggtt	ttaaccaaag	ggggaagaag	tctatatattt	5100
cagaggtggt	catcacagaa	ttagctgtaa	taactaaaga	aaacctgac	atatcaacca	5160
tatgtccaat	aatgaaagag	tagtcagtaa	attaacattg	tgatgtttat	atagacaata	5220
gaaaacattg	tcaatataaa	ctgaaaaaag	cataataaac	agttatatatt	atactacatt	5280
tgcaactaaa	tgaacataat	tataaatgtt	gacaaaggaa	ggaggagtat	ggcaagatga	5340
aaagaattgc	tttaagggtt	atatatgttt	ttattttttt	aataatgc	tattttgtga	5400
ttttaaaaag	ttactgtcgt	agtgttgc	attttttgta	acatcactat	atgtactttt	5460

-continued

ctcttttttag	tatggacctg	tatttagttt	taccatggta	ggcaagacat	ttacttacct	5520
tctggggagt	gatgctgctg	cactgctttt	taatagtaaa	aatgaagacc	tgaatgcaga	5580
agatgtctac	agtcgcctga	caacacctgt	gtttgggaag	ggagttgcat	acgatgtgcc	5640
taatccagta	ggtgacactg	ttaccataaa	taaagacaaa	tctatacctc	agtagttata	5700
gctaatagtg	agacattata	catttaaaat	gtagaacag	ccaggcatgg	tggtcattc	5760
ctgtaatccc	agcactttgg	gaggccaagg	tggtgggac	actcaaagtc	aggagttcaa	5820
gaccagcctg	gccaacatgg	tgaaccctg	tctctactaa	aaatacaaaa	attagctggg	5880
tggggctggt	ggtgcacacc	tgtaaattcc	agctacttgg	gaggtgagg	catgagaatc	5940
gcttgaaccc	aggaggcgga	ggttgcatg	agccgagac	acaacactgc	acttttagcct	6000
tggcaacaga	gtgagacct	gtctcaaaaa	cagaacaaaa	aaaccaaaaa	cacacacaca	6060
cacgcacgag	cacacacaca	cacacacaca	cacacacaga	aaccaaccaa	acaaaaatgt	6120
aataaaatgt	agaaccagtt	tattccttgg	ttcaaaagtc	tgaagaatca	tgagaagaaa	6180
ggccatggat	aactgataag	taatgggtat	ttagttttat	atttgcctgc	atggctaaac	6240
aatattaaag	ggcttctctg	acaaataatg	gaatcaatga	taacttagca	tactgggatt	6300
taatttgaag	gggtatttag	acaatgctgt	tacttcatca	aaaggacttc	ctgcctaccc	6360
attctgcct	gaaattctaa	cataagcgct	gtttagagat	tgtgacttc	agaagtcctc	6420
ttttaatgca	acaacttcac	gtgtggggta	catctatgtg	tatgttttac	cctcaaaagc	6480
caaatacgaa	attgttttaa	gttgatatag	aacacaaatc	agacaattgg	ccccaatgct	6540
tggtatgggc	tctggctgtg	aatgtaacac	acattagcca	gtaccctagt	atagcagtta	6600
agagttaaca	ttaaactctg	tttctagtga	tggggaatga	gggaatgaat	gcctctcctt	6660
aaggccaaaa	aacaggggcc	tggaaaatcc	ctctgttcag	atatatatat	tcathtagac	6720
tctattcatt	tagagtcaga	tagatctatt	catttagact	cttaaaatgt	aaatgccccaa	6780
agggttaaaa	ccattacttg	tgttagtggt	acataattat	aataacctaa	atggatttta	6840
tgataaaaca	aaaatgtggt	ttaatgccgt	atccccgttt	tgaatttttt	tgaagggttt	6900
cttgagcag	aagaaaatgt	taaaaagtgg	ccttaacata	gcccaactta	aacagcatgt	6960
ttctataatt	gaaaaagaaa	caaaggaata	ctttgagagt	tggggagaaa	gtggagaaaa	7020
aagtaagcaa	aatgttttat	gtttgtccta	acatttctac	ttctctgtga	atagaaaagt	7080
agagtatata	tgtgtgtagt	atataaaaaa	caaattacag	tgtatgtaaa	actaccttag	7140
atttatggga	gggttatgta	atgattacca	tgaagttgta	actgagaatc	cagtttttat	7200
actgggctgc	aagttaagta	ttgccttcag	aagcaattgc	tgtgcccata	gtaggagca	7260
acatctgccc	acagggcagc	aggaccaggg	gcagcaggtc	actatattct	gggtctggcc	7320
tttggcctct	gtaagagtgc	cagaatcttt	gtttttggta	tacttaagtt	gatattgata	7380
tattttctaa	ccatacaaga	aactgatgta	taaattagaa	tgccaatgta	ataatgcatg	7440
tgagacatat	aattacagca	ccaagaaatc	cagaatattt	actgatattc	tttttattga	7500
caaatataat	tggaaagcca	gatgatcatt	ggaagttcat	ttagtgaatg	tggaattaac	7560
aggaaattaa	ttggataatt	tttattagtt	gtcatcaaat	tatgcttgcc	tggtgcattt	7620
gtctccagtg	ttgggatata	ctaattgggt	attatagttt	tcttttacat	atcgccagta	7680
attccatttt	ggcctgac	ttcctacttt	taacctggga	aataatctga	tctttggcta	7740
ctattccttg	ggaagtacct	tattattgtc	atatgcacta	taaataacct	tttttctgct	7800

-continued

tttgttattg tgacctggaa atcaaataac cacatttatt cttttcatga tgaagtgtc	7860
atgagtgggg ttttgagatg tgtttctggg atctgttttg gctgtttaga gggacaggg	7920
gcttcacatt gtttggttta ttgccctct tgttggtgt acatagtcac atgtctgtct	7980
acagactttt ttgatgata tgaataggat cttgtttctt cttgagttct gtttttaatt	8040
ctcaattttc tttcactttt tggaaatagt aatgagaata atctttttt tctccctaga	8100
tgtgtttgaa gctctttctg agctcataat tttaacagct agccattgtt tgcattgaaa	8160
ggaaatcaga agtcaactca atgaaaagg agcacagctg tatgcagatt tggatggagg	8220
tttcagccat gcagcctggc tcttaccagg ttggctgcct ttgcctagtt tcaggtatgg	8280
ataaagaata tattacacta ggttatttta ctttgataa ttattgtagt gttggtatgc	8340
tttgccttaa caaagataaa aattaaacaa gtaaaacata caaaatgggt aagattatga	8400
atcccccttc tctcataaga attcaagaca aattttcttt atataatgag ctcatttaaa	8460
gtaagtttca gtttattaaa aagggtgattt gttgtctgtc tagtctaata ttttatttat	8520
gtttttgttt ttgagatgga gtcttgcctt gttgcccag ctgtagtga gtggtgtgat	8580
ctcggtcac tgcagtctct gcctcctgtg ttcaagcaat tctcctgcct catcctcctg	8640
agagctggga ctacaggcac gtgccaccat gcccaactaa tttttctatt tttagtagag	8700
acagggttcc atcatgttg ccaggctggt ttcaaaactc tgacctcagg tgatccacct	8760
gcctcagcct cccaaagtgt taggattaca ggcgtgagcc actgagccca gcctagttta	8820
aaagcctgct tacctcacgt attccttacc ctccaggaaag tctctgaact atacctaaaa	8880
gtgatacagc tcttctctag cacttgtttg aaatctttgg tggcttttta ttgtattgtg	8940
aagtttcttt gttttaaata ttgtgtcctt tatttaattt tctgtttctt aaggacagg	9000
actgcctctg atataaagaa atattgctct taggaactga tctatagctt agtgcttagt	9060
gttttgcata ttagtaggct tctgtactt ttgttgattt attggtgttt aggtgacaga	9120
tggggaggag atagattgct agtccctttt cttctatttc tgccccctct atctagtta	9180
agattggaag aggggtggga gtaaaaggaa gagccaggag agattcccta aagttctctg	9240
gaactcatca taccttatat ttgcaaggag ctttgcagtt tcaaaatgtt tcatatata	9300
ttatattaga acaccagca cagccctgga ctcatagtg gttctccata aatgtgcatt	9360
tctttttttt tttttttttt ttggtgatgg agtcttgcct tctcgcccag gctggagtgc	9420
agtggcatga gctcggtcca ctgcaagctc tgcctccag gttcacgcca ttctcctgcc	9480
tcagcctccc gagtagctgg gactacaggc acccgccacc aagcctggct aattgttttg	9540
tacttttagt agagatgggg ttccaccgtg ttagccagga tggctctgat cctccgacct	9600
tgtgatccgc ccgcctcggc ctcccatagt gctgggatta caggcgtgag ccaactgcacc	9660
tggcccataa atgtacattt ctacctgcct gtttctacct gctctgtctc ttggatgaag	9720
tcagagcttg ctatgttagg ccttccacat tctggcccag tctttctttc ttctactcat	9780
accaactaat ttaaccagat tattcaattc actttcttaa acaggcctat gttttcctgg	9840
ttcgactgta ttcatacagt taagcccaa catcttctct tctgtacaca tggtttcagt	9900
tgatcctcaa taacagatta acagtctgtt aaatgaaaca gagtaggagt tttttttaga	9960
aggcttgatt taagaggggg cttgggagtc agactgccta gttttaaatt ccagctccaa	10020
tgtttgcttt ctgtgtgac ttatgcagct agctataact tgagggttaat agtatgtacc	10080
tcacaggaag ataaaagtga gtaattcatg taaaacactt aacatggtac ctgctacata	10140
gtgaacatac tatttaaagg taaagtttag gagttgaagc ttgtttctg aatctgctag	10200

-continued

tattttcacc	ccctacaaaa	aactattgta	ttagaaagtg	aaaagtagaa	ccagattcca	10260
tggaagaacc	agagtgaactc	ttctgcttta	agacttgatt	tggtattaaa	attggaattt	10320
tatgttaatt	taaaagagta	tctactttc	tggtgaactg	gaaaatactt	ctaaaggaat	10380
ttcttgcttg	ttttaggcct	ttagtttgaa	cacaggcaat	gtgttaagaa	tctgggatat	10440
atatgttaaa	taaagcacag	ttcttgccct	tagggactat	ggacattttt	aacaatgtaa	10500
gattttcatg	acttocagta	tggtcctggg	tctgattttt	ttgtcaatta	tttttagagtc	10560
attaaagttg	gttaataaag	atgctttatg	ctcggtcctg	gttctcaaaa	tgaatttgat	10620
cctagaaggt	tatttcttta	ttaagaaaa	tcatctttat	cttttaatta	cagacgcagg	10680
gacagagctc	atcgggaaat	caaggatatt	ttctataagg	caatccagaa	acgcagacag	10740
tctcaagaaa	aaattgatga	cattctccaa	actttactag	atgctacata	caagtaagag	10800
ctattcagat	aacatattaa	gctgaagcag	gaaattacac	attaaaacac	agttaaatag	10860
tatttccagt	taaaaaacag	tgatgctggc	aaaaataagtt	ggtagctgtg	atctttggac	10920
tctttaaatt	gttgagacat	aaactattgg	catcctgtgt	cttactgtaa	tcccagtgac	10980
tgggtatggt	aaaagtttgc	taatgaactg	taatggagtc	ttttgtaatc	aaaatcgttt	11040
tgtgctggtc	tgtctcttcc	ctaagagaaa	aaaaactcct	gacttgat	agtcaaatat	11100
aagagaccac	tatacctgaa	aaatgtatc	attatgacac	tttatttaaa	ggttgaggca	11160
tgaaatgtat	ctgccaaaat	gttaaatgtg	tgtctttggg	tcattcctta	gggatgggag	11220
tcctttgact	gatgatgaag	tagcagggat	gcttattgga	ttactcttgg	cagggcagca	11280
tacatcctca	actactagtg	cttgatggg	cttctttttg	gccagagaca	aaacacttca	11340
aaaaaatgt	tatttagaac	agaaaacagt	ctgtggagag	aatctgcctc	ctttaactta	11400
tgaccagggt	tgttggattt	ttcagtttca	ttgctgcctt	atgactttga	ggatctgtgg	11460
ctaattttta	aaagggacaa	tttgagattt	tctatatact	atagcttaaa	ttgatcagct	11520
tctctatttt	tagcaaatc	cctataacct	tacctaaaat	atcttaattg	tattgcttct	11580
tgccattaag	ctttatcaga	tatgttttgg	gttgatggct	tagagatcct	tggggatggt	11640
tctttggtag	ttacttcctc	tgettcaaa	tctggcttct	gtacatagag	gatattatgt	11700
gcatgttggt	tgtcttatga	agtgtagaag	cctctgaatt	acttagaatt	ctgtatgtcc	11760
agagtggcct	gggcatgagc	agagacttct	aaaagtagta	gtagtagtag	taatgaggac	11820
aagacattta	caaatactac	atgcaacttg	ctgggtggaa	aggaagagag	gacaactcac	11880
tgcacaacct	gacattccat	cttgaagca	aaccttggtg	atgcatcctt	cctgttatct	11940
tttgtgcttt	tggtcctata	ttaatatggc	acattacact	gattttcaga	tgtaatttgt	12000
attctgggga	taaatcctac	tttgtcatgg	tgcatagttc	ttctatatag	ttactacata	12060
taaaacttgc	gggtttttgt	tgaggatttt	tgcactata	ttcataaagg	atattgatct	12120
ctagtttcac	tgtgatgtct	ttgactgggt	ttgatatcag	gatcatactc	atctcataga	12180
atgtatttgg	aagtattcct	ttttcttct	aatttttggg	agagtttgtg	gatgattggt	12240
gttaatcctt	ttttacatat	ttgcaaaaat	tcagcagtga	aatcatctag	atctgtgctt	12300
ttctttctga	gaagacttta	cttactaatt	caatttattt	gttacagggt	tattcagata	12360
ttccatttct	tcttatgtca	gtttcagtag	tttatatctc	tctaggaatt	tgccatttct	12420
atctagggtta	cctaatttgt	tggcatacaa	ttgttcatag	tattctcata	atccttttta	12480
tttctgtaag	ctcagtagtg	atgtctcaac	actcattcct	gttttttagta	acttaaaata	12540

-continued

acagcttaac	tgatataatt	acatagcata	aatccatcca	tttaaaatgt	acactttgtg	12600
gttttttagca	tattaagagt	tgggaaacca	tcatcataat	ttaatttttag	aacattttaca	12660
tcaactcccaa	aagagagctg	gtaccacatta	gcagtcacgc	ttcattctcc	ctgactgctg	12720
ccccctggcaa	ccattaatct	ccttttgct	ctgtgagttt	gcctattctg	gatatttcat	12780
gtaaatggga	tcatacaatt	tgtagtcttt	tgtgactacc	ttgtttcact	tagcatgtta	12840
tcagggttct	tccatgttgt	agcatgtatc	agtacttcag	tctttgttat	taccaataat	12900
attccattat	atggatagac	cacattttgt	ttatttgctc	atcagttgat	ggacatttga	12960
gttgtttcca	ccttttaaac	tattatgaat	aatgcgcctc	taaactgttg	tgtactgatt	13020
ttatgtggac	atgtgttttc	aattttgggg	ggtcatacct	aggagtagaa	ttgctgggtt	13080
ataaggtaac	tttgaagaac	tgccagactg	ttttaaaaag	tggctgcacc	actttcaa	13140
ctcactaaac	agtatatgtt	ggctcctgact	tcacccctc	accaaacttg	ttacttgatt	13200
tttttattat	aatagggtgtg	aagtgatact	tttttttttt	tttttgagac	agagtcttgg	13260
tgtgatgccc	aggctctagt	gcaatggcgc	gaccttggt	tactgcaacc	tcggcttccc	13320
aggttcaagc	tattctcctt	cctcagcctc	ccaagtagct	gggtacacac	caccacgcct	13380
ggctaatttt	tgtatttttg	gtagagacaa	ggttgtagca	tattggccag	gctggctctg	13440
aactcctgac	ctcaagtcac	ctgcccgcct	tggcctccca	aagtgtctgg	attacaggtg	13500
tgagccacca	tgcccagttg	gtattttgtt	ttgattttgc	atttccctgg	tgactagtga	13560
tgttgagtgt	cttatgatgt	gttctttggc	tttggtatac	ttctttggag	aaatgtctgc	13620
tcacatcctg	ttcccatatt	taaaatgagt	tgtcttttta	ttattgagtt	gtaagagttc	13680
atctattttt	ttttaatgtg	cttttggtgt	cagagaaact	aatgccta	caaagtgtat	13740
gaagatttat	tctgtgtat	tctcttagt	gtttgtagt	ttcatatctt	acatttaggt	13800
ctttgatcca	ttatgaatta	atttatgtat	atgatgtgag	gtcatcattc	ttttgcatgt	13860
gtttatccag	ttgtcccaca	ctgtttgttg	aaaagactat	tttttccacg	ttgaattgtc	13920
tttgtaaaaa	aatctattat	agccaggcgc	agtggcacgt	gcctgtattc	tcagctactg	13980
agaagctgag	atgggaaggt	cgcttgagct	caggacttgg	ggccagcct	gggcaacata	14040
gcgaacccct	gtctctgaaa	aaataaatac	attttaaaaa	gcctcttgac	cataaattta	14100
aggctttatt	tctggactca	gttctattcc	attgatatgt	ttagtctgat	gccattacgt	14160
agttttgtaa	taagttttga	attcgggagt	gtgagtcctc	tgactttgtc	cttttcaagg	14220
ctgtttatct	actcctagtc	cctttagttt	ccatatgaat	tttgggtca	gtgtgtcagt	14280
ttctgcaaag	aagctagctg	agatttttga	caatgattgc	attgtatcgc	catattaatt	14340
tgggagcaca	attttagtct	ttaaatctgt	gaacatgaga	tgtctttctc	ttattttagt	14400
tctttaattt	ctttcaacaa	tgttttatag	tttttggtgc	acaatgttta	aacttctctt	14460
gttaaatgta	ttcttaagta	ttttattatt	gttatttttt	tgatgttatt	ctttcttctg	14520
ccagtcacaa	tctgctgttg	atccccctgg	gtgaattttt	catttcagtt	ctcatacttc	14580
tcagttcttg	aatttctatt	tggttctcta	aaaaaataat	atattgatat	tctccatttt	14640
actagagata	tctaggcata	ttttgctata	gttctttgaa	cctgtttata	atagctgatt	14700
taaattcatt	atctagtaag	tccaatgtct	gggcttcttc	atggatagtt	tctattaaac	14760
tgcttgcttt	ttctatgtac	tggccatact	ttcctgtttt	ggtgtgtttt	ttgtaatttt	14820
tttgttga	actgtacatt	taaaataatg	tggcaactgt	ggaaatcaga	tgccctcctc	14880
cctgggttta	ttgttgctgg	ctctttgttg	ttgttggtgt	tgctgctgct	gtttgtttac	14940

-continued

tgcgtttcct	ggattaatta	tgtcattcct	tgttcagtga	ggtcactgaa	atctctgctt	15000
gcttacttta	gtgggcatct	aatatttga	cagagattta	ctgaagtget	ttgaacagcc	15060
agtctcctag	cttttgctga	aaggctctgt	atgtgtgtgt	taggggatgt	tattaacact	15120
ccaacaggca	gttacaagtc	tgccttcact	acctgtgtgt	acaggtcagc	cagaggtaaa	15180
agattacagc	ctcttagatc	ttacctgggc	atatgcattg	tcttatacat	atgtgtggcc	15240
ttcaagattc	tcttatgttg	gaacttttca	aagtctcctg	tggacatctt	actccccagt	15300
tttccctttt	aaacttcttg	ttctgtctct	tagcaccaac	tgatatcacc	atctcaggcg	15360
ccttcagtgt	taaacaattt	ttgctaaata	tttttgga	atttgcctctg	gctcctctaa	15420
tagttgttag	gcttctggct	ttcacagctg	ctatagtgtg	catgctgttg	gtttccgggg	15480
ctaccatgga	tttggggaga	ggaggatgaa	agaaatacaa	cttacctac	cacaaagctt	15540
actcttctta	ccaagattca	gatttctttt	tcttgaatta	actctcctta	gattgttgca	15600
agccttttgg	taactctcca	gaattttgaa	aaagttgaca	ttaagattgt	tgctactgtt	15660
ttcatttttt	ggaggagtga	atttttgtag	gttcttactt	cattcttcag	ggcaatcgct	15720
tctgttacct	tgccctcctt	ttccaccatg	gacagtggta	gagcatgata	acccagcca	15780
ccctgaacca	gttacctctg	tacttttagc	tggaaatcaa	gctgtcttgt	actaactaag	15840
aagttaaaact	aattttttgt	actgttgaag	tatgttattt	ataacaatca	ggaaatgctt	15900
tctcatttta	gctcaaggat	ctaaatttac	ttgatcgctg	tataaaagaa	acattaagac	15960
ttagacctcc	tataatgatc	atgatgagaa	tggccagaac	tcctcagggtg	agtatcttgg	16020
ctacatcttc	ccctctatac	ccccagtttt	tatcaaaaag	aagaaatagg	tgggtgtggt	16080
ggttcacacc	tgtaatctca	acactttggg	aggctgaggt	gggaggatca	cttgaggcca	16140
gaatttgaga	ccagcctggg	caacatagtg	agactgacct	catctctaca	aaattttttc	16200
taaaaaattag	ctggccataa	tggccatagc	ctgtgggtccc	agctgcttgg	gaggctgatg	16260
tgggtagatt	gcttgagcct	gggaggttga	aactgcagta	atccatgatc	acgccactgc	16320
attgtgcctt	gggcaacaga	gcaagaccct	gtctcaaaaa	aaataaaaat	aaaaaagaaa	16380
gaaaaaagaaa	agaggaagta	gagtagcata	aaagagattt	ttttaaatta	aaaaagtaga	16440
ataatcactt	ctacctaatc	ttcagtttta	tatactctaa	aaacatattt	ttacctaat	16500
gtagatagta	tacgtgctaa	tctgtttttt	ttttttttga	gacggcatth	cactcttgtt	16560
gcccaggctg	gagtgcagtg	gtgcgatctc	agctcactgc	aacctccgcc	tcccgggttc	16620
aagcaattct	tctgcctcag	cctcccaagt	agctgggatt	acaggggcat	gccaccatgc	16680
ctggctaatt	ttttgtattt	tagtagagat	gggttttacc	catgttggtc	aggctgatct	16740
cgaactcccg	acctcagggtg	atccaccgct	cttgccctcc	caaagtgtctg	ggattacagg	16800
tgtaatcccg	cgcccgccct	acatgcta	ctttaatgct	aatcatgttc	tgcatthttc	16860
tttaacaatt	gggtttttta	aaatcaaa	acatattttt	cttgggtttta	aaaataacat	16920
tttgttgtaa	aaaattgtta	atatgaagt	tacaaattga	tagtgaaagc	ctctctgaaa	16980
ttccaacctt	acctccaagg	cattatgggt	ttgatttgtg	tactgtgtac	ttccaacca	17040
acgttggttc	actggaaatc	atcttgagtt	aaaataattt	ttagtttgcc	tattatctag	17100
ccagttttta	aatatatgta	cagatgggtc	ttgatttatg	tgattcaact	tataattttt	17160
tgacttttatg	atggatttat	caggatgtaa	acctatcata	agtcaaggag	catctgagta	17220
tcccatgtat	attcatgctt	tattacacaa	tgatctgatt	atttgcagc	acatttttta	17280

-continued

attctccta	aatgaa	gtgtg	gctttt	gttt	atagact	gtg	gcagggtata	ccattcctcc	17340
aggacatcag	gtgtgtgt	ttt	ctcccactgt	caatcaaaga	cttaaagact	catgggtaga		17400	
acgcctggac	tttaactctg	atcgctactt	acaggataac	ccagcatcag	gggaaaagtt			17460	
tgcctatgtg	ccatttggag	ctggtaagat	gattatattt	tagattggaa	atgtttgttc			17520	
tgataacata	tttgtctctg	tcaaaatatt	ccgaattgtg	tttacaaatt	atctctccct			17580	
ttcctcatag	ggacattttt	gcaaaacttt	ttaggagaag	aatctttata	agttggagaa			17640	
aaataatttc	tttgtacca	atggaattgt	tccataaatc	cttatataat	gcttcactac			17700	
ttcctaacct	gtctggtttt	attaggctta	atttttatag	aacatccttg	ttttccctta			17760	
caatgggtatt	taaagctctt	tgtggattct	cttttaaaga	accattggag	tcagcacacc			17820	
attcagggaa	taacagatta	ctagcatttc	acaaaaaagc	aaaggcagtc	ttttaaatt			17880	
aaagctcttc	tcgatcgta	gtcaacattt	ttgctctctg	aatatccgta	tgagaaaatg			17940	
gtcttttaaat	ttgggcaggt	tgtgtgtagg	cttgcaaatt	tcatttccag	taagatccta			18000	
aaataattta	gctataacct	tgtttctcca	gtaattttct	tgtccattgg	ttctctgtac			18060	
tgattaaact	atattctatg	cttttagctt	tccaaaggga	tcattttaa	gacagatgac			18120	
ttgtcattgg	tcacactttt	tcacatata	aaggaaaata	taaagtcctt	tgggaacttc			18180	
agatcttaac	tttatgta	aatattaata	ctgtgggtga	taacacaata	tataaaagaa			18240	
tcatagtttt	ttttttgaga	gagtcttgct	ctgtcaccca	gtctggagtg	cagtggcaca			18300	
atctctcagc	tcactgcaac	ctccacctct	gggttcaagt	aattctctgt	ccttagcctc			18360	
ctgagtagct	gggattacag	gtgtgtacca	ccacgctcag	ctaatttttg	agcttttagt			18420	
agagactggg	ttttgccatg	ttggccaggc	tggctctgaa	ttccaggctt	gaagcaatct			18480	
gcccaccttg	gctcccccaca	gtgctgggat	tacaggcggtg	agccatgcca	cctggccaaa			18540	
gaatcagatt	gttaacagat	gggaagagca	ttagttctgt	agcccaaatt	ctgccccaaa			18600	
gaggaatcgt	ttctaaacta	gtaattatct	ggtttccact	tgaactttac	tagaaatggg			18660	
ttgtgggttg	ttcagttacc	ttttatgatg	gtcattctta	tgtttgga	gctgtcattt			18720	
ttagagcctt	atgttaaagc	tgaatctgt	ttctttttta	catctcattt	atagttggtc			18780	
ctaaccatag	tctctgaact	tatattgtat	gaggtatttg	agtacagata	taatgtctcc			18840	
tccatctttt	tttcaactct	tgtgttagtt	tcctagggct	tctgtaacta	attacaatat			18900	
gggtggccta	aaacaataga	aatatattct	atcacagttt	tggaggctgg	aagtgtgaaa			18960	
tcaagggtatt	ggcaggaccg	tgctcctcct	taaggttcta	caggagaatc	cttccttgca			19020	
tcttcctagc	ttctgggtggc	tcttggaac	ccttggttg	taactacatt	gttccaatta			19080	
ctaccctgt	cttcaacagg	ctttcttctt	gttcattgtct	ctgtatctta	acatggcatt			19140	
cttataagga	caccagtc	at	tggtatctaa	agtcagggtc	atctcatctt			19200	
aaataattgt	gtatataaag	atcctatttc	ccaattaaga	tcacattcta	aggttctgga			19260	
tggacttgaa	tttatggggg	gatatatgat	cttacgttaa	tcttggttaa	tatcacatta			19320	
catgtctcta	atttctttac	tcattctttt	acctcgta	tgtgctgttt	atttatgttg			19380	
gtgcatatag	ttcattcatt	ttcataatat	tacattttgt	gaatcatcag	aatttatcta			19440	
ctcttatgtt	gattcaatta	ggatacttct	tgcttggtgc	gattaaatcc	ttggactatt			19500	
cttctgttaa	gccaagcttc	tctttagt	ttatatgtga	aatatggacc	aatgtgtaa			19560	
tgctcatctt	aatgtcact	cctagaaata	agtacagtta	tgggccaagc	aagcactgtg			19620	
ctaagcacta	tcagtttagg	tttttctt	tgatgaaaa	tcttgcaatg	aatgccccaa			19680	

-continued

atcttaagtc aacattcatt gagttttgac aaatgaataa cctttagttt agtccaatgt	19740
atcaatcttt taaatgggta ttgctttctg gccctgtctt aaaatttttg cttagccctt	19800
gagtcatgaa gatattctcc tgttcttctc tactgaaatt tatgctgta gcatcatggt	19860
ttgtgacctt tcttgaatta gtatttgatt atgggtgtgac ataggagtgt aatttcattt	19920
ttcccccatg taatatctag ttattcctgg accttatgtt gaaaagactt gcttttcttc	19980
attggcttgc tttggtgtct gtactgataa tcaaataacc ataaaaatat tctgttctgg	20040
gctctctgct ctgttcatt gatctatttg ttgacctta cctagtacca ctctgtttta	20100
tctttagtct tgaagtcaga ttgaaatca gttttatgtc ctccaactca gttctttttc	20160
caagattgct ttggatatcc taggtccttt gcatttttat atgcatttta gaatcagctt	20220
gtcagtttct acatgggtgt gacttttttag tatattattt tgggttcatt aaatctcatt	20280
ttcttcata catttataat gacatttgag gtttgattgg aaggttttca tattgacttt	20340
taactagggc tttcttgga caaacagaat attctactat attcccaaac tagattacca	20400
tcttatgatt caaactttcc atatatttaa ccagatata tattttcaga aaaagtaatt	20460
ggaaaagtta tgtgatcagt caagtactgt ttctctaaaa tgtggtattg aaaatctcct	20520
ggaattttta ataattcatg ttgttttatg tgaaaagaat gtcatctttt tattatatta	20580
tctgtacatt tgcgttctat ctaaaatgta gataatatca cccaggcta aaaaggatga	20640
gaaagaattt aaactgattc ttataacttt ttcttttttt tagggcgta tcgttgtatt	20700
ggggaaaatt ttgcctatgt tcaaatgaag acaatttggc ccactatgct tcgtttatat	20760
gaatttgatc tcattgatgg atactttccc actgtgaatt atacaactat gattcacacc	20820
cctgaaaacc cagttatccg ttacaaacga agatcaaaat gaaaaagggt gcaaggaacg	20880
aatatatgtg attatcactg taagccacaa aggcattcga agagaatgaa gtgtacaaaa	20940
caactcttgt agtttactgt ttttttaagt gtgtaattct aaaagccagt ttatgattta	21000
ggattttgtt aactgaatgg ttctatcaaa tataatagca ttgaaacat ttctaatag	21060
ttatgatact tatacatgtg ctttcaggaa gttccttggg gaaacaattg ttgagggggg	21120
atctaggtaa ttggcagatt ctaaaataa taatttccag atagtaattt taagagtact	21180
catcgtctct gccaaataag ttcagggtat tcaaatcttg gactagtctt gcaaggata	21240
aagaataaaa atcccagtg gatacttgga aaccacagtt tattattatt tatctgggca	21300
attattgtgt gtgtgaggat ggaagggtag ggaataatcg aacatctaaa gccttgaata	21360
agagaatact aattgttttg gtatgatgat actcagaaat ggagatatta taggaaaaag	21420
aatcccttg gaattttaac taaaatcact gcatatggga aattaagaga tccaggacca	21480
tatttgataa gagttctaa aaataatgta attattaatg ctaaagactg ctcatgtatc	21540
ttgatctaata tactaaataa ttacatattt atttacctga taaatatgta tctagttcta	21600
caaggtcaca tttatgtgga agtccaaagt caagtcctta ggggataatt ttgttttggc	21660
tcagttgttc cctgcttctt tttttttttt ttttttttga gatggagtct cgtctgttg	21720
cccaggctgg agtgacgtgg tgcgatctca gctcactgca tcctctgctt cccgggttca	21780
agcaattctc tgccctagcc tcccaagtag ttgggattac aggcacctgc caccatgcct	21840
ggctaatttt ttgtattttt agtagagacg ggggtttcac tatgttggct aggtgggtct	21900
tgaactctg acctcgtgat ccccccgcct tggcctccca aagtgtctggg attacaggca	21960
tgagccaccg cacctggcct tcctgcttc ctctctagaa tccaattagg gatgtttgtt	22020

-continued

```

actactcata ttgattaaaa cagttaacaa acttttttct ttttaaaatg tgagatcagt 22080
gaactctggt ttttaagataa tctgaacaa ggtccttggg agtaataaaa ttggtcacat 22140
tctgtaaagc acattctggt taggaatcaa cttatctcaa attgtaactc ggggcctaac 22200
tatatgagat ggctgaaaaa ataccacatc gtctgttttc actagggtgat gccaaaaatat 22260
tttgctttat gtatattaca gttcttttta aaacactgga agactcatgt taaactctaa 22320
ttgtgaaggc agaatctctg ctaatttttc agattaaaat tctctttgaa aaaataca 22378

```

```

<210> SEQ ID NO 3
<211> LENGTH: 1659
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

```

```

<400> SEQUENCE: 3

```

```

gttcgttgca acaaatgat gagcaatgct tttttataat gccaaacttg tacaaaaaag 60
ttggcatggc ggcggcggtt gggatgctgc tgctgggctt gctgcaggcg ggtgggtcgg 120
tgctgggcca ggcgatggag aagggtgacag gcggcaacct cttgtccatg ctgctgatcg 180
cctgcgcctt caccctcagc ctgggtctacc tgatcgtct ggccgcggcg caccctggtcc 240
agctgcccgc aggggtgaaa agtccctccat acattttctc cccaattcca ttccttgggc 300
atgccatagc atttgggaaa agtccaattg aatttctaga aaatgcatat gagaagtatg 360
gacctgtatt tagttttacc atggtaggca agacatttac ttacctctg gggagtgatg 420
ctgctgcact gctttttaat agtaaaaatg aagacctgaa tgcagaagat gtctacagtc 480
gcctgacaac acctgtgttt gggaaaggag ttgcatacga tgtgcctaat ccagttttct 540
tgagagcagaa gaaaatgtta aaaagtggcc ttaacatagc ccactttaaa cagcatgttt 600
ctataaattga aaaagaaaca aaggaatact ttgagagtgg gggagaaaagt ggagaaaaaa 660
atgtgtttga agctctttct gagctcataa ttttaacagc tagccattgt ttgcatggaa 720
aggaaatcag aagtcaactc aatgaaaagg tagcacagct gtatgcagat ttggatggag 780
gtttcagcca tgcagcctgg ctcttaccag gttggctgcc tttgcctagt ttcagacgca 840
gggacagagc tcatcgggaa atcaaggata ttttctataa ggcaatccag aaacgcagac 900
agtctcaaga aaaaattgat gacattctcc aaactttact agatgctaca tacaaggatg 960
ggcgtccttt gactgatgat gaagtagcag ggatgcttat tggattactc ttggcagggc 1020
agcatacatc ctcaactact agtgcttggg tgggcttctt tttggccaga gacaaaacac 1080
ttcaaaaaaa atgttattta gaacagaaaa cagctctgtg agagaatctg cctcctttaa 1140
cttatgacca gctcaaggat ctaaatctac ttgatcgctg tataaaagaa acattaagac 1200
ttagacctcc tgtaatgatc atgatgagaa tggccagaac tcctcagact gtggcagggc 1260
ataccattcc tccaggacat cagggtgtgtg tttctcccac tgtcaatcaa agacttaaag 1320
actcatgggt agaacgcctg gactttaatc ctgatcgcta cttacaggat aaccagcat 1380
caggggaaaa gtttgcttat gtgccatttg gagctgggcg tcatcgttgt attggggaaa 1440
attttgccta tgttcaaatt aagacaattt ggtccactat gcttcgttta tatgaatttg 1500
atctcattga tggatacttt ccactgtga attatacaac tatgattcac acccctgaaa 1560
acccagttat ccgttacaaa cgaagatcaa aatgcccaac tttctgttac aaagttggca 1620
ttataagaaa gcattgctta tcaatttgtt gcaacgaac 1659

```

```

<210> SEQ ID NO 4
<211> LENGTH: 85

```

-continued

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 4

aaucuaggag gcaggugcuc acuuguccuc cuccaugcuu ggaaaaugca gggaggaggc 60

cauaguggca acuguuacca ugaau 85

The invention claimed is:

1. A method of treating cancer in a subject, the method comprising administering to the subject a tyrosine kinase inhibitor and an anti-resistance agent, wherein the anti-resistance agent comprises a CYP51A1 inhibitor, or an agonist of SEQ ID NO: 4 (miRNA-764), or a combination thereof, and wherein the cancer is a tyrosine kinase inhibitor-resistant cancer.

2. The method of claim 1, wherein the tyrosine kinase inhibitor and the anti-resistance agent are co-administered to the subject.

3. The method of claim 1, wherein the tyrosine kinase inhibitor is administered to the subject prior to the anti-resistance agent.

4. The method of claim 1, wherein the anti-resistance agent is administered to the subject prior to the tyrosine kinase inhibitor.

5. A method of treating cancer in a subject undergoing treatment with a tyrosine kinase inhibitor, the method comprising administering to the subject an anti-resistance agent,

wherein the anti-resistance agent comprises a CYP51A1 inhibitor, or an agonist of SEQ ID NO: 4 (miRNA-764), or a combination thereof, and wherein the cancer is a tyrosine kinase inhibitor-resistant cancer.

6. The method of claim 1, wherein the cancer comprises non-small cell lung cancer (NSCLC).

7. The method of claim 1, wherein acquired drug resistance to the tyrosine kinase inhibitor is decreased or prevented.

8. The method of claim 7, wherein tyrosine kinase inhibitor resistance is decreased at least 2-fold.

9. The method of claim 7, wherein tyrosine kinase inhibitor resistance is decreased at least 5-fold.

10. The method of claim 7, wherein the activity of the tyrosine kinase inhibitor is increased at least 2-fold.

11. The method of claim 7, wherein the activity of the tyrosine kinase inhibitor is increased at least 5-fold.

12. The method of claim 1, wherein the tyrosine kinase inhibitor comprises lapatinib.

* * * * *